Profiles
Joanne Dickinson
UTAS Home Professor Joanne Dickinson
Joanne Dickinson
Principal Research Fellow
Menzies Institute for Medical Research; and
Centre for Law and Genetics
Hobart CBD Campuses
+61 3 6226 7622 (phone)
The vast majority of people's lives are affected by cancer. Some people are more likely to develop cancer than others, with some developing more aggressive cancers and others milder forms of disease. Also, some respond well to treatment and others don't. Professor of cancer genetics, Jo Dickinson, is trying to find out why.
Understanding the genetics that lead to cancer
The vast majority of people's lives are affected by cancer. Some people are more likely to develop cancer than others, with some developing more aggressive cancers and others milder forms of disease. Also, some respond well to treatment and others do not. Professor of cancer genetics, Jo Dickinson, is trying to find out why.
'Genetics determines everything about you. What you look like, how your body works, your risk of disease, how you respond to infections, how you respond to chemicals, even your response to your environment, like sun,' said Professor Dickinson.
'I want to understand the genetic factors that lead to certain cancers, why some people develop aggressive cancers and what determines our response to treatment.'
'If we know what genetic factors lead to a particular cancer, then we can test people for them. We can profile their risk, which could lead to earlier detection. We can target our treatments to more effectively treat cancers and hopefully stop the disease from being life threatening,' said Professor Dickinson.
One such discovery made by Professor Dickinson is the role of a sticky molecule, or protein, that sits on the surface of cells, and plays an important role in the spread of cells. This protein is now being investigated as a target for new cancer therapies.
'This was a significant discovery because if we can prevent cancer cells from spreading we could cure a lot of cancers.
'Currently, most cancers require severe treatments like chemotherapy or radiotherapy. Unfortunately these treatments can have many side effects because we don't know which are the best treatments to use for each type of cancer. Also, these treatments aren't effective for everyone and we don't know why.
'For example, radiotherapy is only effective in treating about half of the men diagnosed with prostate cancer, and we don't know which men will respond best to treatment. If we knew, we would only treat the men that radiotherapy is likely to be effective for. We need to find the genetic basis for people's response to therapy,' said Professor Dickinson.
'To understand the genetic basis of disease, we need to conduct research in people affected with disease. One useful approach is to study families with multiple members affected by the same disease.'
Professor Dickinson said that Tasmania is an ideal place to contribute to this globally significant issue due to its stable and isolated population.
'There is great scope to work with multiple generations of families, which is essential to understanding the genetic basis for cancer.'
'We have a great relationship with the community. People in Tasmania are happy to be involved because they are very supportive of the health research and the Menzies.
'Our biggest barrier currently is the shrinking amount of funding devoted to medical research. I believe there is a valuable opportunity for businesses to step in and become involved in promoting and supporting health research.
'Large dollars go into advertising and sponsorship which surrounds some of the more highly profitable professional sport and entertainment industries, but if businesses really want to leave a positive footprint in their communities, funding groundbreaking health research is another option with a lasting and positive impact.'
Professor Joanne Dickinson is a cancer genetics researcher based at Menzies Institute for Medical Research and in the Centre for Law and Genetics at the University of Tasmania. She was a National Health and Medical Research Council (NHMRC) funded scholar for her PhD in pathology focusing on cancer research. Professor Dickinson's research interests are in understanding how inherited differences in genes contribute to the development of different types of cancers including blood and prostate cancer. She is also interested in how inherited differences in genes influence how disease progresses. Her important contributions over her career include one of the earliest reports of a new role for a group of proteins in cell death in cancer. Her important contributions to our understanding the genetic basis of disease has included inherited eye disease and most recently prostate cancer and tumour spread.
Career summary
Qualifications
- PhD (Pathology), University of Queensland, Australia, 1996
- BSc (Hons - Pathology), University of Queensland, Australia, 1996
Memberships
Other
Professor Dickinson is a current member of the National Breast Cancer Foundation Research Advisory Committee, and a NHMRC project grant panel member in 2011,2012 and 2013. She reviews for the ARC and Cancer Australia. She has acted as a grant reviewer for the Wellcome Trust, Medical Research Council (UK) and nationally she has reviewed annually for the NHMRC project grant scheme (since 2005), the NHMRC Centre for Clinical Research Excellence Scheme in 2010 and 2011, the Leukaemia Foundation and Diabetes Australia. Assoc Prof Dickinson reviews for a variety of journals including Molecular Cancer Therapeutics,PloS One, and Genes and Immunity. She is also Deputy Chair of the Human Research Ethics Committee (Tasmania Network).
Teaching
Teaching expertise
Professor Dickinson's contributions to research training include supervision of PhD and Honours students.
View more on Professor Joanne Dickinson in WARP
Research Themes
Professor Dickinson's research aligns with one of the University's key research themes of Better Health. She leads one of the five research Themes (Cancer, Genetics and Immunology) at the University of Tasmania's Menzies Institute for Medical Research. Her administrative responsibilities includes management of four research groups within this theme. Professor Dickinson's primary research interest is in the discovery of genetic contributors to complex diseases, the focus being the genetic study of large families with multiple cases of disease ascertained from the Tasmanian population. The Tasmanian familial genetic resources now established have been recognized both nationally and internationally. Building the genetic research capabilities of the in-house genetics facility has been her primary focus over the past two years. She has built genetic analysis infrastructure generating hi-throughput genetic and epigenetic analysis capabilities, computing facilities capable of handling large volumes of data, in addition to attracting skilled bioinformatics and genetics expertise.
Fields of Research
- Cancer genetics (321103)
- Medical genetics (excl. cancer genetics) (320213)
- Oncology and carcinogenesis (321199)
- Epidemiology (420299)
- Molecular targets (321108)
- Cancer cell biology (321101)
- Genetics (310599)
- Epigenetics (incl. genome methylation and epigenomics) (310504)
- Respiratory diseases (320103)
- Ophthalmology (321201)
- Haematology (320102)
- Gene expression (incl. microarray and other genome-wide approaches) (310505)
- Genomics (310509)
- Cancer diagnosis (321102)
- Preventative health care (420605)
- Solid tumours (321111)
- Health services and systems (420399)
- Marine and estuarine ecology (incl. marine ichthyology) (310305)
- Cellular immunology (320404)
- Bioethics (500101)
- Medical and health law (480412)
- Predictive and prognostic markers (321109)
- Biochemistry and cell biology (310199)
- Neurology and neuromuscular diseases (320905)
- Medical biochemistry and metabolomics (320599)
- Haematological tumours (321106)
- Neurogenetics (310511)
- Property law (excl. intellectual property law) (480604)
- Clinical chemistry (incl. diagnostics) (320202)
- Occupational and workplace health and safety (350505)
- Medical biochemistry - nucleic acids (320505)
- Cancer therapy (excl. chemotherapy and radiation therapy) (321104)
- Implementation science and evaluation (420312)
- Aboriginal and Torres Strait Islander public health and wellbeing (450417)
- Probability theory (490506)
- Disease surveillance (420202)
- Paediatrics (321399)
- Bioassays (340102)
- Biodiscovery (410301)
- Ecological impacts of climate change and ecological adaptation (410102)
- Climate change impacts and adaptation (410199)
- Genetic immunology (310507)
- Health and community services (420305)
- Immunology (320499)
- Plant cell and molecular biology (310803)
- Genome structure and regulation (310508)
- Central nervous system (320903)
- Primary health care (420319)
- Pathology (excl. oral pathology) (320220)
- Health care administration (420306)
- Mental health services (420313)
- Rural sociology (441003)
- Physiotherapy (420106)
- Aquaculture (300501)
- Anaesthesiology (320201)
- Applied ethics (500199)
- Separation science (340109)
- Medical biotechnology (320699)
- Applied statistics (490501)
- People with disability (420318)
- Sport and exercise nutrition (321006)
- Cell and nuclear division (310502)
- Software engineering (461299)
- Information extraction and fusion (460507)
- Biocatalysis and enzyme technology (310601)
- Foetal development and medicine (321501)
- Microbial ecology (310703)
- Health informatics and information systems (420308)
- Health counselling (420307)
- Geriatrics and gerontology (320210)
- Clinical pharmacology and therapeutics (321402)
Research Objectives
- Clinical health (200199)
- Diagnosis of human diseases and conditions (200101)
- Treatment of human diseases and conditions (200105)
- Men's health (200504)
- Expanding knowledge in the biomedical and clinical sciences (280103)
- Expanding knowledge in the biological sciences (280102)
- Other health (209999)
- Preventive medicine (200412)
- Evaluation of health outcomes (200202)
- Expanding knowledge in the health sciences (280112)
- Assessment and management of Antarctic and Southern Ocean ecosystems (180403)
- Law reform (230405)
- Public health (excl. specific population health) (200499)
- Marine biodiversity (180504)
- Bioethics (130301)
- Prevention of human diseases and conditions (200104)
- Disease distribution and transmission (incl. surveillance and response) (200404)
- Aboriginal and Torres Strait Islander determinants of health (210301)
- Health inequalities (200204)
- Specific population health (excl. Indigenous health) (200599)
- Environmental lifecycle assessment (190204)
- Assessment and management of terrestrial ecosystems (180601)
- Health status (incl. wellbeing) (200407)
- Expanding knowledge in economics (280108)
- Rural and remote area health (200508)
- Mental health (200409)
- Human diagnostics (240802)
- Efficacy of medications (200102)
- Fisheries - aquaculture (100299)
- Mental health services (200305)
- Health related to ageing (200502)
- Allied health therapies (excl. mental health services) (200301)
- Dental health (200402)
- Neonatal and child health (200506)
- Wild caught fin fish (excl. tuna) (100305)
- Health education and promotion (200203)
- Evaluation of health and support services (200299)
- Human pharmaceutical products (240899)
- Other Indigenous (219999)
- Adolescent health (200501)
- Behaviour and health (200401)
- Expanding knowledge in the environmental sciences (280111)
- Application software packages (220401)
Publications
Total publications
119
Highlighted publications
(12 outputs)| Year | Type | Citation | Altmetrics |
|---|---|---|---|
| 2017 | Journal Article | Blackburn NB, Marthick JR, Banks A, Charlesworth JC, Marsden KA, et al., 'Evaluating a CLL susceptibility variant in ITGB2 in families with multiple sub-types of hematological malignancies', Blood, 130, (1) pp. 86-88. ISSN 0006-4971 (2017) [Refereed Article] DOI: 10.1182/blood-2017-03-774232 [eCite] [Details] Citations: Scopus - 1Web of Science - 3 Co-authors: Blackburn NB; Marthick JR; Banks A; Charlesworth JC; Lowenthal RM | |
| 2015 | Journal Article | Atashrazm F, Lowenthal RM, Woods GM, Holloway AF, Dickinson JL, 'Fucoidan and cancer: a multifunctional molecule with anti-tumor potential', Marine Drugs, 13, (4) pp. 2327-2346. ISSN 1660-3397 (2015) [Refereed Article] DOI: 10.3390/md13042327 [eCite] [Details] Citations: Scopus - 200Web of Science - 187 Co-authors: Lowenthal RM; Woods GM; Holloway AF | |
| 2013 | Journal Article | Al Olama AA, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, et al., 'A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease', Human Molecular Genetics, 22, (2) pp. 408-415. ISSN 0964-6906 (2013) [Refereed Article] DOI: 10.1093/hmg/dds425 [eCite] [Details] Citations: Scopus - 111Web of Science - 98 Co-authors: Fitzgerald LM; Marthick JR; Patterson B | |
| 2011 | Journal Article | Kote-Jarai Z, Al Olama AA, Giles GG, Severi G, Schleutker J, et al., 'Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study', Nature Genetics, 43, (8) pp. 785-791. ISSN 1061-4036 (2011) [Refereed Article] DOI: 10.1038/ng.882 [eCite] [Details] Citations: Scopus - 245Web of Science - 224 Co-authors: Fitzgerald L; Marthick JR; Patterson B | |
| 2011 | Journal Article | Tegg EM, Thomson RJ, Stankovich JM, Banks A, Marsden KA, et al., 'Anticipation in familial hematologic malignancies', Blood, 117, (4) pp. 1308-1310. ISSN 0006-4971 (2011) [Refereed Article] DOI: 10.1182/blood-2010-07-296475 [eCite] [Details] Citations: Scopus - 13Web of Science - 9 Co-authors: Tegg EM; Thomson RJ; Stankovich JM; Banks A; Marsden KA; Lowenthal RM; Foote SJ | |
| 2009 | Journal Article | Eeles RA, Kote-Jarai Z, Amin Al Olama A, Giles GG, Guy M, et al., 'Identification of seven new prostate cancer susceptibility loci through a genome-wide association study', Nature Genetics, 41, (10) pp. 1116-1121. ISSN 1061-4036 (2009) [Refereed Article] DOI: 10.1038/ng.450 [eCite] [Details] Citations: Scopus - 356Web of Science - 334 Co-authors: Fitzgerald LM; Polanowski AM; Patterson B; The UK ProtecT Study The PRACTICAL Consortium | |
| 2009 | Journal Article | Fitzgerald LM, Patterson B, Thomson RJ, Polanowski AM, Quinn SJ, et al., 'Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and sporadic disease', European Journal of Human Genetics, 17 pp. 368-377. ISSN 1018-4813 (2009) [Refereed Article] DOI: 10.1038/ejhg.2008.171 [eCite] [Details] Citations: Scopus - 22Web of Science - 22 Co-authors: Fitzgerald LM; Patterson B; Thomson RJ; Polanowski AM; Quinn SJ; Mackey DA; Dwyer T; Foote SJ; Stankovich J; McKay JD | |
| 2008 | Journal Article | Dwyer T, Van der Mei IAF, Ponsonby AL, Taylor BVM, Stankovich J, et al., 'Melanocortin 1 receptor genotype, past environmental sun exposure, and risk of multiple sclerosis', Neurology, 71, (8) pp. 583-589. ISSN 0028-3878 (2008) [Refereed Article] DOI: 10.1212/01.wnl.0000323928.57408.93 [eCite] [Details] Citations: Scopus - 39Web of Science - 37 Co-authors: Dwyer T; Van der Mei IAF; Ponsonby AL; Taylor BVM; Stankovich J; Thomson Russell; Polanowski AM | |
| 1999 | Journal Article | Fingert JH, Heon E, Liebmann JM, Yamamoto T, Craig JE, et al., 'Analysis of myocilin mutations in 1703 glaucoma patients from five different populations', Human Molecular Genetics, 8, (5) pp. 899-905. ISSN 0964-6906 (1999) [Refereed Article] DOI: 10.1093/hmg/8.5.899 [eCite] [Details] Citations: Scopus - 485Web of Science - 438 Co-authors: Mackey DA | |
| 1998 | Journal Article | Antalis TM, Linn ML, Donnan K, Mateo L, Gardner J, et al., 'The serine proteinase inhibitor (Serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta priming', Journal of Experimental Medicine, 187, (11) pp. 1799-1811. ISSN 0022-1007 (1998) [Refereed Article] DOI: 10.1084/jem.187.11.1799 [eCite] [Details] Citations: Scopus - 77Web of Science - 67 | |
| 1998 | Journal Article | Dickinson JL, Norris BJ, Jensen PH, Antalis TM, 'The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF- induced apoptosis', Cell Death and Differentiation, 5, (2) pp. 163-171. ISSN 1350-9047 (1998) [Refereed Article]DOI: 10.1038/sj.cdd.4400324 [eCite] [Details] Citations: Scopus - 64Web of Science - 56 | |
| 1995 | Journal Article | Dickinson JL, Bates EJ, Ferrante A, Antalis TM, 'Plasminogen activator inhibitor type 2 inhibits tumour necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function', Journal of Biological Chemistry, 270, (46) pp. 27894-27904. ISSN 0021-9258 (1995) [Refereed Article] DOI: 10.1074/jbc.270.46.27894 [eCite] [Details] Citations: Scopus - 227Web of Science - 221 |
Journal Article
(94 outputs)| Year | Citation | Altmetrics |
|---|---|---|
| 2023 | Foley GR, Marthick JR, Ostrander EA, Stanford JL, Dickinson JL, et al., 'Association of a novel BRCA2 mutation with prostate cancer risk further supports germline genetic testing', European Journal of Cancer, 180 pp. 155-157. ISSN 1879-0852 (2023) [Letter or Note in Journal] DOI: 10.1016/j.ejca.2022.11.034 [eCite] [Details] Co-authors: Foley GR; Marthick JR; Fitzgerald LM | |
| 2023 | Nelson N, Feurstein S, Niaz A, Truong J, Holien JK, et al., 'Functional genomics for curation of variants in telomere biology disorder associated genes: A systematic review', Genetics in Medicine, 25, (3) Article 100354. ISSN 1098-3600 (2023) [Refereed Article] DOI: 10.1016/j.gim.2022.11.021 [eCite] [Details] Co-authors: Lucas S; Fairfax K | |
| 2023 | Nelson N, Feurstein S, Niaz N, Truong J, Holien JK, et al., 'Functional genomics for curation of variants in telomere biology disorder associated genes: A systematic review', Genetics in Medicine, 25, (3) pp. 1-18. ISSN 1098-3600 (2023) [Refereed Article] DOI: 10.1016/j.gim.2022.11.021 [eCite] [Details] Co-authors: Lucas S; Fairfax K | |
| 2023 | Peljto AL, Blumhagen RZ, Walts AD, Cardwell J, Powers J, et al., 'Idiopathic pulmonary fibrosis is associated with common genetic variants and limited rare variants', American Journal of Respiratory and Critical Care Medicine ISSN 1073-449X (2023) [Refereed Article] | |
| 2022 | Dickinson JL, Foley GR, Fitzgerald LM, 'Re: Daniel J. Lee, Ryan Hausler, Anh N. Le, et al. Association of inherited mutations in DNA repair genes with localized prostate cancer. Eur Urol 2022;81:559-67', European Urology, 81 pp. 559-67. ISSN 0302-2838 (2022) [Letter or Note in Journal] DOI: 10.1016/j.eururo.2022.08.026 [eCite] [Details] Citations: Web of Science - 10 Co-authors: Foley GR; Fitzgerald LM | |
| 2022 | Foley GR, Blizzard CL, Stokes B, Skala M, Redwig F, et al., 'Urban-rural prostate cancer disparities in a regional state of Australia', Scientific Reports, 12 Article 3022. ISSN 2045-2322 (2022) [Refereed Article] DOI: 10.1038/s41598-022-06958-2 [eCite] [Details] Citations: Web of Science - 1 Co-authors: Foley GR; Blizzard CL; Stokes B; Fitzgerald LM | |
| 2022 | Lucas SEM, Raspin K, Mackintosh J, Glaspole I, Reynolds NP, et al., 'Preclinical interstitial lung disease in relatives of familial pulmonary fibrosis patients', Pulmonology pp. 1-4. ISSN 2531-0437 (2022) [Refereed Article] DOI: 10.1016/j.pulmoe.2022.09.002 [eCite] [Details] Citations: Web of Science - 3 Co-authors: Lucas SEM; Raspin K; Wood-Baker R; Walters EH | |
| 2022 | Raspin K, Marthick JR, Donovan S, Blizzard L, Malley RC, et al., 'Identification of a novel recurrent EEF2 gene amplification in familial prostate tumors', Genes, Chromosomes and Cancer pp. 1-9. ISSN 1045-2257 (2022) [Refereed Article] DOI: 10.1002/gcc.23117 [eCite] [Details] Co-authors: Raspin K; Marthick JR; Blizzard L; Malley RC; Banks A; FitzGerald LM | |
| 2022 | Raspin K, O'Malley DE, Marthick JR, Donovan S, Malley RC, et al., 'Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition', Prostate, 82, (5) pp. 540-550. ISSN 0270-4137 (2022) [Refereed Article] DOI: 10.1002/pros.24300 [eCite] [Details] Citations: Scopus - 2Web of Science - 1 Co-authors: Raspin K; Marthick JR; Banks A; Fitzgerald LM | |
| 2022 | Verhoeff TF, Holloway AF, Dickinson JL, 'Non-coding RNA regulation of integrins and their potential as therapeutic targets in cancer', Cellular Oncology pp. 1-12. ISSN 2211-3436 (2022) [Refereed Article] DOI: 10.1007/s13402-022-00752-y [eCite] [Details] Citations: Web of Science - 2 Co-authors: Verhoeff TF; Holloway AF | |
| 2022 | Verhoeff TJ, Holloway AF, Dickinson JL, 'A novel long non‑coding RNA regulates the integrin, ITGA2 in breast cancer', Breast Cancer Research and Treatment, 192 pp. 89-100. ISSN 0167-6806 (2022) [Refereed Article] DOI: 10.1007/s10549-021-06496-x [eCite] [Details] Citations: Scopus - 2Web of Science - 2 Co-authors: Verhoeff TJ; Holloway AF | |
| 2021 | Karlsson Q, Brook MN, Dadaev T, Wakerell S, Saunders EJ, et al., 'Rare germline variants in ATM predispose to prostate cancer: A PRACTICAL Consortium study', European Urology Oncology ISSN 2588-9311 (2021) [Refereed Article] DOI: 10.1016/j.euo.2020.12.001 [eCite] [Details] Citations: Scopus - 19Web of Science - 20 Co-authors: Fitzgerald LM | |
| 2021 | Mackintosh JA, Pietsch M, Lutzky V, Enever D, Bancroft S, et al., 'TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis', BMJ Open Respiratory Research, 8, (1) Article 001127. ISSN 2052-4439 (2021) [Refereed Article] DOI: 10.1136/bmjresp-2021-001127 [eCite] [Details] Citations: Scopus - 5Web of Science - 6 | |
| 2021 | Marthick JR, Raspin K, Foley GR, Blackburn NB, Banks A, et al., 'Massively parallel sequencing in hereditary prostate cancer families reveals a rare risk variant in the DNA repair gene, RAD51C', European Journal of Cancer, 159 pp. 52-55. ISSN 0959-8049 (2021) [Refereed Article] DOI: 10.1016/j.ejca.2021.09.038 [eCite] [Details] Citations: Scopus - 2Web of Science - 1 Co-authors: Marthick JR; Raspin K; Foley GR; Blackburn NB; Banks A; Malley RC; Fitzgerald LM | |
| 2021 | Raspin K, Fitzgerald LM, Marthick JR, Field MA, Malley RC, et al., 'A rare variant in EZH2 is associated with prostate cancer risk', International Journal of Cancer pp. 1-11. ISSN 0020-7136 (2021) [Refereed Article] DOI: 10.1002/ijc.33584 [eCite] [Details] Citations: Scopus - 4Web of Science - 4 Co-authors: Raspin K; Fitzgerald LM; Marthick JR; Malley RC; Banks A; Foley GR | |
| 2021 | Tegart LJ, Johnston Fay, Borchers Arriagada N, Workman A, Dickinson JL, et al., ' Pollen potency': the relationship between atmospheric pollen counts and allergen exposure', Aerobiologia ISSN 0393-5965 (2021) [Refereed Article] DOI: 10.1007/s10453-021-09726-3 [eCite] [Details] Citations: Scopus - 6Web of Science - 5 Co-authors: Tegart LJ; Johnston Fay; Borchers Arriagada N; Workman A; Jones PJ | |
| 2020 | Wilkinson EJ, Woodworth AM, Parker M, Phillips JL, Malley RC, et al., 'Epigenetic regulation of the ITGB4 gene in prostate cancer', Experimental Cell Research, 392, (2) pp. 1-10. ISSN 0014-4827 (2020) [Refereed Article] DOI: 10.1016/j.yexcr.2020.112055 [eCite] [Details] Citations: Scopus - 6Web of Science - 6 Co-authors: Wilkinson EJ; Woodworth AM; Parker M; Phillips JL; Malley RC; Holloway AF | |
| 2019 | McWhirter RE, Otahal P, Taylor-Thomson D, Maypilama EL, Rumbold AR, et al., 'Recurrence patterns identify aggressive form of human papillomavirus-dependent vulvar cancer', Australian and New Zealand Journal of Obstetrics and Gynaecology pp. 1-7. ISSN 0004-8666 (2019) [Refereed Article] DOI: 10.1111/ajo.13075 [eCite] [Details] Citations: Web of Science - 1 Co-authors: McWhirter RE; Otahal P | |
| 2018 | De Paoli-Iseppi R, Deagle BE, Polanowski AM, McMahon CR, Dickinson JL, et al., 'Age estimation in a long-lived seabird (Ardenna tenuirostris) using DNA methylation-based biomarkers', Molecular Ecology Resources, 19, (2) pp. 411-425. ISSN 1755-098X (2018) [Refereed Article] DOI: 10.1111/1755-0998.12981 [eCite] [Details] Citations: Scopus - 26Web of Science - 24 Co-authors: De Paoli-Iseppi R; Deagle BE; Polanowski AM; McMahon CR; Hindell MA | |
| 2018 | De Paoli-Iseppi R, Prentice L, Marthick JR, Thomson R, Holloway AF, et al., 'Multiple endocrine neoplasia type 1: clinical correlates of MEN1 gene methylation', Pathology, 50, (6) pp. 622-628. ISSN 0031-3025 (2018) [Refereed Article] DOI: 10.1016/j.pathol.2018.05.006 [eCite] [Details] Citations: Scopus - 3Web of Science - 5 Co-authors: De Paoli-Iseppi R; Prentice L; Marthick JR; Thomson R; Holloway AF; Burgess J | |
| 2018 | Perera AP, Sajnani K, Dickinson J, Eri R, Korner H, 'NLRP3 inflammasome in colitis and colitis-associated colorectal cancer', Mammalian Genome, 29, (11-12) pp. 817-830. ISSN 0938-8990 (2018) [Refereed Article] DOI: 10.1007/s00335-018-9783-2 [eCite] [Details] Citations: Scopus - 34Web of Science - 31 Co-authors: Perera AP; Eri R; Korner H | |
| 2018 | Phillips JL, Taberlay PC, Woodworth AM, Hardy K, Brettingham-Moore KH, et al., 'Distinct mechanisms of regulation of the ITGA6 and ITGB4 genes by RUNX1 in myeloid cells', Journal of Cellular Physiology, 233, (4) pp. 3439-3453. ISSN 0021-9541 (2018) [Refereed Article] DOI: 10.1002/jcp.26197 [eCite] [Details] Citations: Scopus - 10Web of Science - 10 Co-authors: Phillips JL; Taberlay PC; Woodworth AM; Brettingham-Moore KH; Holloway AF | |
| 2018 | de Vos A, Faux CE, Marthick J, Dickinson J, Jarman SN, 'New determination of prey and parasite species for Northern Indian Ocean blue whales', Frontiers in Marine Science, 5, (APR) Article 104. ISSN 2296-7745 (2018) [Refereed Article] DOI: 10.3389/fmars.2018.00104 [eCite] [Details] Citations: Scopus - 16Web of Science - 14 Co-authors: Marthick J | |
| 2017 | Blackburn NB, Marthick JR, Banks A, Charlesworth JC, Marsden KA, et al., 'Evaluating a CLL susceptibility variant in ITGB2 in families with multiple sub-types of hematological malignancies', Blood, 130, (1) pp. 86-88. ISSN 0006-4971 (2017) [Refereed Article] DOI: 10.1182/blood-2017-03-774232 [eCite] [Details] Citations: Scopus - 1Web of Science - 3 Co-authors: Blackburn NB; Marthick JR; Banks A; Charlesworth JC; Lowenthal RM | |
| 2017 | De Paoli-Iseppi R, Deagle BE, McMahon CR, Hindell MA, Dickinson JL, et al., 'Measuring animal age with DNA methylation: from humans to wild animals', Frontiers in Genetics, 8 Article 106. ISSN 1664-8021 (2017) [Refereed Article] DOI: 10.3389/fgene.2017.00106 [eCite] [Details] Citations: Scopus - 40Web of Science - 39 Co-authors: De Paoli-Iseppi R; Deagle BE; Hindell MA | |
| 2017 | De Paoli-Iseppi R, Polanowski AM, McMahon C, Deagle BE, Dickinson JL, et al., 'DNA methylation levels in candidate genes associated with chronological age in mammals are not conserved in a long-lived seabird', PLoS One, 12, (12) Article e0189181. ISSN 1932-6203 (2017) [Refereed Article] DOI: 10.1371/journal.pone.0189181 [eCite] [Details] Citations: Scopus - 3Web of Science - 3 Co-authors: De Paoli-Iseppi R; McMahon C; Hindell MA | |
| 2017 | FitzGerald LM, Raspin K, Marthick JR, Field MA, Malley RC, et al., 'Impact of the G84E variant on HOXB13 gene and protein expression in formalin-fixed, paraffin-embedded prostate tumours', Scientific Reports, 7, (1) Article 17778. ISSN 2045-2322 (2017) [Refereed Article] DOI: 10.1038/s41598-017-18217-w [eCite] [Details] Citations: Scopus - 7Web of Science - 7 Co-authors: FitzGerald LM; Raspin K; Marthick JR; Malley RC; Blackburn NB; Banks A; Charlesworth JC | |
| 2017 | Nicol D, Eckstein L, Morrison M, Sherkow JS, Otlowski M, et al., 'Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic', Genome Medicine, 9, (1) Article 85. ISSN 1756-994X (2017) [Contribution to Refereed Journal] DOI: 10.1186/s13073-017-0475-4 [eCite] [Details] Citations: Scopus - 11Web of Science - 9 Co-authors: Nicol D; Eckstein L; Otlowski M; Burdon KP; Chalmers D; Charlesworth J; Hewitt AW; Mackey DA; Nielsen J; McWhirter RE | |
| 2017 | Nicol D, McWhirter R, Dickinson J, 'Implementing values-based governance for a new bioresource model', Journal of Law and the Biosciences, 4, (2) pp. 404-411. ISSN 2053-9711 (2017) [Refereed Article] DOI: 10.1093/jlb/lsx007 [eCite] [Details] Citations: Scopus - 1 Co-authors: Nicol D; McWhirter R | |
| 2016 | Atashrazm F, Lowenthal RM, Dickinson JL, Holloway AF, Woods GM, 'Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo', OncoTarget, 7, (29) pp. 46028-46041. ISSN 1949-2553 (2016) [Refereed Article] DOI: 10.18632/oncotarget.10016 [eCite] [Details] Citations: Scopus - 16Web of Science - 13 Co-authors: Lowenthal RM; Holloway AF; Woods GM | |
| 2016 | Cazaly E, Thomson R, Marthick JR, Holloway AF, Charlesworth J, et al., 'Comparison of pre-processing methodologies for Illumina 450k methylation array data in familial analyses', Clinical Epigenetics, 8, (1) Article 75. ISSN 1868-7083 (2016) [Refereed Article] DOI: 10.1186/s13148-016-0241-2 [eCite] [Details] Citations: Scopus - 9Web of Science - 6 Co-authors: Cazaly E; Thomson R; Marthick JR; Holloway AF; Charlesworth J | |
| 2016 | Nicol D, Bubela T, Chalmers D, Charbonneau J, Critchley C, et al., 'Precision medicine: drowning in a regulatory soup?', Journal of Law and the Biosciences, 3, (2) pp. 281-303. ISSN 2053-9711 (2016) [Refereed Article] DOI: 10.1093/jlb/lsw018 [eCite] [Details] Citations: Scopus - 17Web of Science - 17 Co-authors: Nicol D; Chalmers D; Charbonneau J; Hewitt AW; McWhirter R; Otlowski M | |
| 2015 | Amin Al Olama A, Benlloch S, Antoniou AC, Giles GG, Severi G, et al., 'Risk analysis of prostate cancer in PRACTICAL, a multinational consortium, using 25 known prostate cancer susceptibility loci', Cancer Epidemiology, Biomarkers and Prevention, 24, (7) pp. 1121-1129. ISSN 1055-9965 (2015) [Refereed Article] DOI: 10.1158/1055-9965.EPI-14-0317 [eCite] [Details] Citations: Scopus - 52Web of Science - 48 Co-authors: Fitzgerald L | |
| 2015 | Atashrazm F, Lowenthal RM, Woods GM, Holloway AF, Dickinson JL, 'Fucoidan and cancer: a multifunctional molecule with anti-tumor potential', Marine Drugs, 13, (4) pp. 2327-2346. ISSN 1660-3397 (2015) [Refereed Article] DOI: 10.3390/md13042327 [eCite] [Details] Citations: Scopus - 200Web of Science - 187 Co-authors: Lowenthal RM; Woods GM; Holloway AF | |
| 2015 | Atashrazm F, Lowenthal RM, Woods GM, Holloway AF, Karpiniec SS, et al., 'Fucoidan suppresses the growth of human acute promyelocytic leukemia cells in vitro and in vivo', Journal of Cellular Physiology, 231, (3) pp. 688-697. ISSN 0021-9541 (2015) [Refereed Article] DOI: 10.1002/jcp.25119 [eCite] [Details] Citations: Scopus - 32Web of Science - 30 Co-authors: Lowenthal RM; Woods GM; Holloway AF | |
| 2015 | Blackburn NB, Charlesworth JC, Marthick JR, Tegg EM, Marsden KA, et al., 'A retrospective examination of mean relative telomere length in the Tasmanian Familial Hematological Malignancies Study', Oncology Reports, 33, (1) pp. 25-32. ISSN 1791-2431 (2015) [Refereed Article] DOI: 10.3892/or.2014.3568 [eCite] [Details] Citations: Scopus - 9Web of Science - 9 Co-authors: Blackburn NB; Charlesworth JC; Marthick JR; Tegg EM; Marsden KA; Lowenthal RM | |
| 2015 | Cazaly E, Charlesworth J, Dickinson JL, Holloway AF, 'Genetic determinants of epigenetic patterns: providing insight into disease', Molecular Medicine, 21 pp. 400-409. ISSN 1076-1551 (2015) [Refereed Article] DOI: 10.2119/molmed.2015.00001 [eCite] [Details] Citations: Scopus - 8Web of Science - 8 Co-authors: Cazaly E; Charlesworth J; Holloway AF | |
| 2015 | Chin PS, Marthick JR, West AC, Short AK, Chuckowree J, et al., 'Regulation of the ITGA2 gene by epigenetic mechanisms in prostate cancer', The Prostate, 75, (7) pp. 723-734. ISSN 0270-4137 (2015) [Refereed Article] DOI: 10.1002/pros.22954 [eCite] [Details] Citations: Scopus - 22Web of Science - 22 Co-authors: Chin PS; Marthick JR; West AC; Short AK; Chuckowree J; Polanowski AM; Thomson RJ; Holloway AF | |
| 2015 | Qadi A, Taberlay PC, Phillips JL, Young A, West AC, et al., 'The leukemia inhibitory factor receptor gene is a direct target of RUNX1', Journal of Cellular Biochemistry, 117, (1) pp. 49-58. ISSN 0730-2312 (2015) [Refereed Article] DOI: 10.1002/jcb.25246 [eCite] [Details] Citations: Scopus - 6Web of Science - 5 Co-authors: Taberlay PC; Phillips JL; Young A; West AC; Brettingham-Moore KH; Holloway AF | |
| 2014 | Chalmers D, McWhirter RE, Nicol D, Whitton T, Otlowski M, et al., 'New avenues within community engagement: addressing the ingenuity gap in our approach to health research and future provision of health care', Journal of Responsible Innovation, 1, (3) pp. 321-328. ISSN 2329-9460 (2014) [Refereed Article] DOI: 10.1080/23299460.2014.963002 [eCite] [Details] Citations: Scopus - 9 Co-authors: Chalmers D; McWhirter RE; Nicol D; Whitton T; Otlowski M; Critchley C | |
| 2014 | McWhirter RE, Critchley CR, Nicol D, Chalmers DRC, Whitton TC, et al., 'Community Engagement for Big Epidemiology: Deliberative Democracy as a Tool', Journal of Personalized Medicine, 4, (4) pp. 459-474. ISSN 2075-4426 (2014) [Refereed Article] DOI: 10.3390/jpm4040459 [eCite] [Details] Co-authors: McWhirter RE; Critchley CR; Nicol D; Chalmers DRC; Whitton TC; Otlowski MFA | |
| 2014 | McWhirter RE, Marthick JR, Boyle JA, Dickinson JL, 'Genetic and epigenetic variation in vulvar cancer: Current research and future clinical practice', The Australian and New Zealand Journal of Obstetrics and Gynaecology, 54, (5) pp. 406-411. ISSN 1479-828X (2014) [Refereed Article] DOI: 10.1111/ajo.12241 [eCite] [Details] Citations: Scopus - 6Web of Science - 5 Co-authors: McWhirter RE; Marthick JR | |
| 2014 | McWhirter RE, Thomson RJ, Marthick JR, Rumbold AR, Brown MA, et al., 'Runs of homozygosity and a cluster of vulvar cancer in young Australian Aboriginal women', Gynecologic Oncology, 133, (3) pp. 421-426. ISSN 0090-8258 (2014) [Refereed Article] DOI: 10.1016/j.ygyno.2014.03.566 [eCite] [Details] Citations: Scopus - 13Web of Science - 12 Co-authors: McWhirter RE; Thomson RJ; Marthick JR | |
| 2014 | Young A, Berry R, Holloway AF, Blackburn NB, Dickinson JL, et al., 'RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization', BMC Cancer, 14 Article 808. ISSN 1471-2407 (2014) [Refereed Article] DOI: 10.1186/1471-2407-14-808 [eCite] [Details] Citations: Scopus - 26Web of Science - 25 Co-authors: Young A; Berry R; Holloway AF; Blackburn NB; Phillips JL; Brettingham-Moore KH | |
| 2013 | Al Olama AA, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, et al., 'A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease', Human Molecular Genetics, 22, (2) pp. 408-415. ISSN 0964-6906 (2013) [Refereed Article] DOI: 10.1093/hmg/dds425 [eCite] [Details] Citations: Scopus - 111Web of Science - 98 Co-authors: Fitzgerald LM; Marthick JR; Patterson B | |
| 2013 | Lowenthal RM, Tegg EM, Dickinson JL, 'The Familial Tasmanian Haematological Malignancies Study (FaTHMS): its origins, its history and the phenomenon of anticipation', Transfusion and Apheresis Science, 49, (2) pp. 113-115. ISSN 1473-0502 (2013) [Contribution to Refereed Journal] DOI: 10.1016/j.transci.2013.07.011 [eCite] [Details] Citations: Scopus - 3Web of Science - 3 Co-authors: Lowenthal RM; Tegg EM | |
| 2013 | McWhirter RE, Nicol D, Chalmers D, Dickinson JL, 'Body ownership and research', Journal of Law and Medicine, 21 pp. 323-329. ISSN 1320-159X (2013) [Refereed Article] PMID: 24597380 [eCite] [Details] Co-authors: McWhirter RE; Nicol D; Chalmers D | |
| 2012 | Marthick JR, Dickinson JL, 'Emerging Putative Biomarkers: The Role of Alpha 2 and 6 Integrins in Susceptibility, Treatment and Prognosis', Prostate Cancer, 2012 Article 298732. ISSN 2090-3111 (2012) [Refereed Article] DOI: 10.1155/2012/298732 [eCite] [Details] Co-authors: Marthick JR | |
| 2012 | McWhirter RE, Mununggirritj D, Marika D, Dickinson JL, Condon JR, 'Ethical genetic research in Indigenous communities: challenges and successful approaches', Trends in Molecular Medicine, 18, (12) pp. 702-708. ISSN 1471-4914 (2012) [Refereed Article] DOI: 10.1016/j.molmed.2012.08.003 [eCite] [Details] Citations: Scopus - 12Web of Science - 17 Co-authors: McWhirter RE | |
| 2011 | Chin SP, Dickinson JL, Holloway AF, 'Epigenetic regulation of prostate cancer', Clinical Epigenetics, 2, (2) pp. 151-169. ISSN 1868-7075 (2011) [Refereed Article] DOI: 10.1007/s13148-011-0041-7 [eCite] [Details] Citations: Scopus - 30Web of Science - 24 Co-authors: Chin SP; Holloway AF | |
| 2011 | Ellis JA, Ponsonby AL, Pezic A, Williamson E, Cochrane JA, et al., 'APOE Genotype and Cardio-Respiratory Fitness Interact to Determine Adiposity in 8-Year-Old Children from the Tasmanian Infant Health Survey', PL o S One, 6, (11) Article e26679. ISSN 1932-6203 (2011) [Refereed Article] DOI: 10.1371/journal.pone.0026679 [eCite] [Details] Citations: Scopus - 12Web of Science - 11 Co-authors: Ponsonby AL; Cochrane JA; Dwyer T | |
| 2011 | Kote-Jarai Z, Al Olama AA, Giles GG, Severi G, Schleutker J, et al., 'Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study', Nature Genetics, 43, (8) pp. 785-791. ISSN 1061-4036 (2011) [Refereed Article] DOI: 10.1038/ng.882 [eCite] [Details] Citations: Scopus - 245Web of Science - 224 Co-authors: Fitzgerald L; Marthick JR; Patterson B | |
| 2011 | Ritchie ME, Liu R, Carvalho BS, Bahlo M, Booth DR, et al., 'Comparing genotyping algorithms for Illumina's Infinium whole-genome SNP BeadChips', BMC Bioinformatics, 12 Article 68. ISSN 1471-2105 (2011) [Refereed Article] DOI: 10.1186/1471-2105-12-68 [eCite] [Details] Citations: Scopus - 36Web of Science - 41 Co-authors: Foote SJ; Stankovich J; Taylor BV; Drysdale K; Guru P; Hoban E; McMorran BJ; Polanowski A; Whittock L; Perera D | |
| 2011 | Tegg EM, Thomson RJ, Stankovich JM, Banks A, Marsden KA, et al., 'Anticipation in familial hematologic malignancies', Blood, 117, (4) pp. 1308-1310. ISSN 0006-4971 (2011) [Refereed Article] DOI: 10.1182/blood-2010-07-296475 [eCite] [Details] Citations: Scopus - 13Web of Science - 9 Co-authors: Tegg EM; Thomson RJ; Stankovich JM; Banks A; Marsden KA; Lowenthal RM; Foote SJ | |
| 2010 | Bahlo M, Stankovich J, Danoy P, Hickey PF, Taylor BV, et al., 'Saliva-Derived DNA Performs Well in Large-Scale, High-Density Single-Nucleotide Polymorphism Microarray Studies', Cancer Epidemiology, Biomarkers and Prevention, 19, (3) pp. 794-798. ISSN 1055-9965 (2010) [Refereed Article] DOI: 10.1158/1055-9965.EPI-09-0812 [eCite] [Details] Citations: Scopus - 44Web of Science - 41 Co-authors: Stankovich J; Taylor BV; Foote SJ; Drysdale K; Guru P; Hoban E; McMorran BJ; Polanowski A; Whittock L; Perera D | |
| 2010 | Simon KC, van der Mei IAF, Munger KL, Ponsonby A, Dickinson J, et al., 'Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk', Neurology, 74, (17) pp. 1365-1371. ISSN 0028-3878 (2010) [Refereed Article] DOI: 10.1212/WNL.0b013e3181dad57e [eCite] [Details] Citations: Scopus - 124Web of Science - 109 Co-authors: van der Mei IAF; Ponsonby A; Dwyer T | |
| 2010 | Tegg EM, Thomson RJ, Stankovich J, Banks A, Flowers C, et al., 'Evidence for a common genetic aetiology in high-risk families with multiple haematological malignancy subtypes ', British Journal of Haematology, 150, (4) pp. 456-462. ISSN 0007-1048 (2010) [Refereed Article] DOI: 10.1111/j.1365-2141.2010.08267.x [eCite] [Details] Citations: Scopus - 7Web of Science - 7 Co-authors: Tegg EM; Thomson RJ; Stankovich J; Banks A; Flowers C; McWhirter R; Panton J; Piaszczyk A; Bahlo M; Marsden KA; Lowenthal RM; Foote SJ | |
| 2010 | van der Mei IAF, Ponsonby AL, Taylor BV, Stankovich J, Dickinson JL, et al., 'Human Leukocyte Antigen-DR15, Low Infant Sibling Exposure and Multiple Sclerosis: Gene-Environment Interaction', Annals of Neurology, 67, (2) pp. 261-265. ISSN 0364-5134 (2010) [Refereed Article] DOI: 10.1002/ana.21849 [eCite] [Details] Citations: Scopus - 20Web of Science - 20 Co-authors: van der Mei IAF; Ponsonby AL; Taylor BV; Stankovich J; Foote S; Dwyer T | |
| 2009 | Dickinson JL, Perera DI, van der Mei AF, Ponsonby AL, Polanowski AM, et al., 'Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 Vitamin D receptor variant in this interaction ', Multiple Sclerosis, 15, (5) pp. 563-570. ISSN 1352-4585 (2009) [Refereed Article] DOI: 10.1177/1352458509102459 [eCite] [Details] Citations: Scopus - 78Web of Science - 71 Co-authors: Perera DI; van der Mei AF; Ponsonby AL; Polanowski AM; Thomson RJ; Taylor BV; Stankovich J; Dwyer T | |
| 2009 | Eeles RA, Kote-Jarai Z, Amin Al Olama A, Giles GG, Guy M, et al., 'Identification of seven new prostate cancer susceptibility loci through a genome-wide association study', Nature Genetics, 41, (10) pp. 1116-1121. ISSN 1061-4036 (2009) [Refereed Article] DOI: 10.1038/ng.450 [eCite] [Details] Citations: Scopus - 356Web of Science - 334 Co-authors: Fitzgerald LM; Polanowski AM; Patterson B; The UK ProtecT Study The PRACTICAL Consortium | |
| 2009 | Fitzgerald LM, Patterson B, Thomson RJ, Polanowski AM, Quinn SJ, et al., 'Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and sporadic disease', European Journal of Human Genetics, 17 pp. 368-377. ISSN 1018-4813 (2009) [Refereed Article] DOI: 10.1038/ejhg.2008.171 [eCite] [Details] Citations: Scopus - 22Web of Science - 22 Co-authors: Fitzgerald LM; Patterson B; Thomson RJ; Polanowski AM; Quinn SJ; Mackey DA; Dwyer T; Foote SJ; Stankovich J; McKay JD | |
| 2008 | Dwyer T, Blizzard L, Patterson B, Ponsonby A-L, Martin K, et al., 'Association between birth weight and adolescent systolic blood pressure in a caucasian birth cohort differs according to skin type, CRH promoter or 11β-HSD2 genotype', Archives of Disease in Childhood, 93, (9) pp. 760-767. ISSN 0003-9888 (2008) [Refereed Article] DOI: 10.1136/adc.2007.129122 [eCite] [Details] Citations: Scopus - 3Web of Science - 3 Co-authors: Dwyer T; Blizzard L; Patterson B; Ponsonby A-L; Martin K; Quinn S; Sale MM; Richards SM | |
| 2008 | Dwyer T, Van der Mei IAF, Ponsonby AL, Taylor BVM, Stankovich J, et al., 'Melanocortin 1 receptor genotype, past environmental sun exposure, and risk of multiple sclerosis', Neurology, 71, (8) pp. 583-589. ISSN 0028-3878 (2008) [Refereed Article] DOI: 10.1212/01.wnl.0000323928.57408.93 [eCite] [Details] Citations: Scopus - 39Web of Science - 37 Co-authors: Dwyer T; Van der Mei IAF; Ponsonby AL; Taylor BVM; Stankovich J; Thomson Russell; Polanowski AM | |
| 2008 | Fitzgerald LM, Thomson RJ, Polanowski AM, Patterson B, McKay JD, et al., 'Sequence variants of α-methylacyl-CoA racemase are associated with prostate cancer risk: A replication study in an ethnically homogeneous population', The Prostate, 68, (13) pp. 1373-1379. ISSN 0270-4137 (2008) [Refereed Article] DOI: 10.1002/pros.20798 [eCite] [Details] Citations: Scopus - 11Web of Science - 11 Co-authors: Fitzgerald LM; Thomson RJ; Polanowski AM; Patterson B; Stankovich J | |
| 2008 | Ponsonby AL, Blizzard CL, Pezic A, Cochrane JA, Ellis JA, et al., 'Adiposity Gain During Childhood, ACE I/D Polymorphisms and Metabolic Outcomes', Obesity, 16, (9) pp. 2141-2147. ISSN 1930-7381 (2008) [Refereed Article] DOI: 10.1038/oby.2008.302 [eCite] [Details] Citations: Scopus - 14Web of Science - 11 Co-authors: Ponsonby AL; Blizzard CL; Cochrane JA; Sale MM; Richards SM; Dwyer T | |
| 2008 | Wray BN, Stankovich J, Whittock LD, Dwyer T, Ponsonby AL, et al., 'CTLA-4 and multiple sclerosis: The A49G single nucleotide polymorphism shows no association with multiple sclerosis in a Southern Australian population', Journal of Neuroimmunology, 196, (1-2) pp. 139-142. ISSN 0165-5728 (2008) [Refereed Article] DOI: 10.1016/j.jneuroim.2008.02.001 [eCite] [Details] Citations: Scopus - 11Web of Science - 10 Co-authors: Wray BN; Stankovich J; Whittock LD; Van der Mei IAF; Taylor BVM; Foote SJ; McMorran BJ | |
| 2007 | Thomson Russell, Quinn SJ, McKay JD, Silver J, Bahlo M, et al., 'The advantages of dense marker sets for linkage analysis with very large families', Human Genetics, 121, (3-4) pp. 459-468. ISSN 0340-6717 (2007) [Refereed Article] DOI: 10.1007/s00439-007-0323-5 [eCite] [Details] Citations: Scopus - 2Web of Science - 2 Co-authors: Thomson Russell; Quinn SJ; McKay JD; Fitzgerald LM; Foote SJ; Stankovich J | |
| 2006 | Dickinson JL, Sale MM, Passmore A, Fitzgerald LM, Wheatley CM, et al., 'Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity', Clinical and Experimental Ophthalmology, 34, (7) pp. 682-688. ISSN 1442-6404 (2006) [Refereed Article] DOI: 10.1111/j.1442-9071.2006.01314.x [eCite] [Details] Citations: Scopus - 72Web of Science - 62 Co-authors: Sale MM; Passmore A; Fitzgerald LM; Burdon KP; Mackey DA | |
| 2004 | Burdon KP, Wirth MG, Mackey DA, Russell-Eggitt IM, Craig JE, et al., 'A novel mutation in the Connexin 46 gene causes autosomal dominant congenital cataract with incomplete penetrance', Journal of Medical Genetics, 41, (8) pp. e106-109. ISSN 0022-2593 (2004) [Refereed Article] DOI: 10.1136/jmg.2004.018333 [eCite] [Details] Citations: Scopus - 56Web of Science - 51 Co-authors: Burdon KP; Mackey DA; Craig JE; Sale MM | |
| 2004 | Burdon KP, Wirth MG, Mackey DA, Russell-Eggitt IM, Craig JE, et al., 'Investigation of crystallin genes in familial cataract, and report of two disease associated mutations', British Journal of Ophthalmology , 88, (1) pp. 79-83. ISSN 0007-1161 (2004) [Refereed Article] DOI: 10.1136/bjo.88.1.79 [eCite] [Details] Citations: Scopus - 70Web of Science - 58 Co-authors: Burdon KP; Mackey DA; Craig JE; Sale MM | |
| 2004 | Dwyer T, Stankovich J, Blizzard CL, Fitzgerald LM, Dickinson JL, et al., 'Does the Addition of Information on Genotype Improve Prediction of the Risk of Melanoma and Nonmelanoma Skin Cancer beyond That Obtained from Skin Phenotype?', American Journal of Epidemiology, 159, (9) pp. 826-833. ISSN 0002-9262 (2004) [Refereed Article] DOI: 10.1093/aje/kwh120 [eCite] [Details] Citations: Scopus - 58Web of Science - 50 Co-authors: Dwyer T; Stankovich J; Blizzard CL; Fitzgerald LM; Reilly A; Sale MM | |
| 2003 | Burdon KP, Wilkinson RM, Barbour JM, Dickinson JL, Stankovich J, et al., 'Investigation of albinism genes in congenital esotropia', Molecular Vision, 9, (83-85 ) pp. 710-714. ISSN 1090-0535 (2003) [Refereed Article] PMID: 14685142 [eCite] [Details] Citations: Scopus - 8Web of Science - 6 Co-authors: Burdon KP; Stankovich J; Mackey DA; Sale MM | |
| 2002 | Rubio J, Bahlo M, Butzkueven H, Van der Mei IAF, Sale MM, et al., 'Genetic dissection of the human leukocyte antigen region by use of haplotypes of Tasmanians with multiple sclerosis', American Journal of Human Genetics, 70, (5) pp. 1125-1137. ISSN 0002-9297 (2002) [Refereed Article] DOI: 10.1086/339932 [eCite] [Details] Citations: Scopus - 85Web of Science - 78 Co-authors: Van der Mei IAF; Sale MM; Groom PS; Taylor BVM; Dwyer T; Foote SJ | |
| 2002 | Sale MM, Craig JE, Charlesworth JC, Fitzgerald LM, Hanson I, et al., 'Broad Phenotypic variability in a Single Pedigree With a Novel 1410delC Mutation in the PST Domain of the PAX6 Gene', Human Mutation, 20, (4) pp. 322. ISSN 1098-1004 (2002) [Refereed Article] DOI: 10.1002/humu.9066 [eCite] [Details] Citations: Scopus - 32Web of Science - 39 Co-authors: Sale MM; Craig JE; Charlesworth JC; Fitzgerald LM; Mackey DA | |
| 2002 | Sale MM, Fitzgerald LM, Kagame K, Erdmann I, Craig JE, et al., 'Investigation of the prevalence of the myocilin Q368STOP mutation in Ugandan glaucoma patients', Ophthalmic Genetics, 33, (1) pp. 67-69. ISSN 1381-6810 (2002) [Letter or Note in Journal] Co-authors: Sale MM; Fitzgerald LM; Craig JE | |
| 2002 | Stankovich J, Sale MM, Cooley H, Bahlo M, Reilly A, et al., 'Investigation of chromosome 2q in osteoarthritis of the hand: no significant linkage in a Tasmanian population', Annals of the Rheumatic Diseases, 61, (12) pp. 1081-1084. ISSN 0003-4967 (2002) [Refereed Article] DOI: 10.1136/ard.61.12.1081 [eCite] [Details] Citations: Scopus - 15Web of Science - 12 Co-authors: Stankovich J; Sale MM; Cooley H; Reilly A; Jones G | |
| 2002 | Vickers JC, Craig JE, Stankovich J, McCormack GH, West AK, et al., 'The apolipoprotein epsilon 4 gene is associated with elevated risk of normal tension glaucoma', Molecular Vision, 8, (40) pp. 389-393. ISSN 1090-0535 (2002) [Refereed Article] Citations: Web of Science - 71 Co-authors: Vickers JC; Craig JE; Stankovich J; McCormack GH; West AK; McCartney PJ; Mackey DA | |
| 2002 | Wheatley C, Dickinson JL, Mackey DA, Craig JE, Sale MM, 'Retinopathy of prematurity: recent advances in our understanding', British Journal of Ophthalmology, 86, (6) pp. 696-701. ISSN 0007-1161 (2002) [Refereed Article] DOI: 10.1136/bjo.86.6.696 [eCite] [Details] Citations: Scopus - 88Web of Science - 68 Co-authors: Wheatley C; Mackey DA; Craig JE; Sale MM | |
| 2002 | Wheatley C, Dickinson JL, Mackey DA, Craig JE, Sale MM, 'Retinopathy of prematurity: recent advances in our understanding', Archives of Disease in Childhood, 87, (2) pp. F78-F82. ISSN 0003-9888 (2002) [Refereed Article] DOI: 10.1136/fn.87.2.F78 [eCite] [Details] Citations: Web of Science - 52 Co-authors: Wheatley C; Mackey DA; Craig JE; Sale MM | |
| 2001 | Baird PN, Dickinson JL, Craig JE, Mackey DA, 'The Taa1 Restriction Enzyme Provides a Simple Means to Identify the Q368STOP Mutation of the Myocilin Gene in Primary Open Angle Glaucoma', American Journal of Ophthalmology, 131, (4) pp. 510-511. ISSN 0002-9394 (2001) [Refereed Article] DOI: 10.1016/S0002-9394(00)00812-6 [eCite] [Details] Citations: Scopus - 9Web of Science - 5 Co-authors: Mackey DA | |
| 2001 | Craig JE, Baird PN, Healey DL, McNaught AI, McCartney PJ, et al., 'Evidence for Genetic Heterogeneity within Eight Glaucoma Families, with the GLC1A Gln368STOP Mutation Being an Important Phenotypic Modifier', Ophthalmology, 108, (9) pp. 1607-1620. ISSN 0161-6420 (2001) [Refereed Article] DOI: 10.1016/S0161-6420(01)00654-6 [eCite] [Details] Citations: Scopus - 98Web of Science - 82 Co-authors: Craig JE; Mackey DA | |
| 2001 | Dickinson JL, Sale MM, Craig JE, Mackey DA, 'Laboratory methods in ophthalmic genetics: obtaining DNA from patients', Ophthalmic Genetics, 22, (1) pp. 49-60. ISSN 1381-6810 (2001) [Professional, Non Refereed Article] Co-authors: Sale MM; Craig JE; Mackey DA | |
| 1999 | Fingert JH, Heon E, Liebmann JM, Yamamoto T, Craig JE, et al., 'Analysis of myocilin mutations in 1703 glaucoma patients from five different populations', Human Molecular Genetics, 8, (5) pp. 899-905. ISSN 0964-6906 (1999) [Refereed Article] DOI: 10.1093/hmg/8.5.899 [eCite] [Details] Citations: Scopus - 485Web of Science - 438 Co-authors: Mackey DA | |
| 1999 | Hooper JD, Nicol DL, Dickinson JL, Eyre HJ, Scarman AL, et al., 'Testisin, a New Human Serine Proteinase Expressed by Premeiotic Testicular Germ Cells and Lost in Testicular Germ Cell Tumors', Cancer Research, 59, (13) pp. 3199-3205. ISSN 0008-5472 (1999) [Refereed Article] PMID: 10397266 [eCite] [Details] Citations: Scopus - 98Web of Science - 83 | |
| 1998 | Antalis TM, Linn ML, Donnan K, Mateo L, Gardner J, et al., 'The serine proteinase inhibitor (Serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta priming', Journal of Experimental Medicine, 187, (11) pp. 1799-1811. ISSN 0022-1007 (1998) [Refereed Article] DOI: 10.1084/jem.187.11.1799 [eCite] [Details] Citations: Scopus - 77Web of Science - 67 | |
| 1998 | Dickinson JL, Norris BJ, Jensen PH, Antalis TM, 'The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF- induced apoptosis', Cell Death and Differentiation, 5, (2) pp. 163-171. ISSN 1350-9047 (1998) [Refereed Article] DOI: 10.1038/sj.cdd.4400324 [eCite] [Details] Citations: Scopus - 64Web of Science - 56 | |
| 1998 | Mahony D, Stringer BW, Dickinson JL, Antalis TM, 'DNase I hypersensitive sites in the 5 ' flanking region of the human plasminogen activator inhibitor type 2 (PAI-2) gene are associated with basal and tumor necrosis factor-alpha-induced transcription in monocytes', European Journal of Biochemistry, 256, (3) pp. 550-559. ISSN 0014-2956 (1998) [Refereed Article] DOI: 10.1046/j.1432-1327.1998.2560550.x [eCite] [Details] Citations: Scopus - 5Web of Science - 5 | |
| 1997 | Dong Y, Berners-Price SJ, Thorburn DR, Antalis T, Dickinson J, et al., 'Serine protease inhibition and mitochondrial dysfunction associated with cisplatin resistance in human tumor cell lines: targets for therapy', Biochemical Pharmacology, 53, (11) pp. 1673-82. ISSN 0006-2952 (1997) [Refereed Article] DOI: 10.1016/s0006-2952(97)00015-4 [eCite] [Details] Citations: Scopus - 44Web of Science - 41 | |
| 1996 | Wang XQ, Gabrielli BG, Milligan A, Dickinson JL, Antalis TM, et al., 'Accumulation of p16CDKN2A in response to ultraviolet irradiation correlates with late S-G(2)-phase cell cycle delay', Cancer Research, 56, (11) pp. 2510-2514. ISSN 0008-5472 (1996) [Refereed Article] Citations: Web of Science - 61 | |
| 1995 | Dickinson JL, Bates EJ, Ferrante A, Antalis TM, 'Plasminogen activator inhibitor type 2 inhibits tumour necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function', Journal of Biological Chemistry, 270, (46) pp. 27894-27904. ISSN 0021-9258 (1995) [Refereed Article] DOI: 10.1074/jbc.270.46.27894 [eCite] [Details] Citations: Scopus - 227Web of Science - 221 | |
| 1993 | Dickinson JL, Antalis TM, 'Tissue factor and plasminogen activator inhibitor expression in the differentiation of myeloid leukemic cells', Leukemia, 7, (6) pp. 864-871. ISSN 0887-6924 (1993) [Refereed Article] Citations: Web of Science - 14 | |
| 1993 | Reeder JA, Dickinson JL, Chenevix-Trench G, Antalis TM, 'Sodium butyrate differentially modulates plasminogen activator inhibitor type-1 urokinase plasminogen activator, and its receptor in a human colon carcinoma cell', Teratogenesis, Carcinogenesis, and Mutagenesis, 13, (2) pp. 75-88. ISSN 0270-3211 (1993) [Refereed Article] DOI: 10.1002/tcm.1770130204 [eCite] [Details] Citations: Scopus - 15Web of Science - 15 | |
| 1992 | Antalis TM, Dickinson JL, 'Control of plasminogen-activator inhibitor type 2 gene expression in the differentiation of monocytic cells', European Journal of Biochemistry, 205, (1) pp. 203-209. ISSN 0014-2956 (1992) [Refereed Article] DOI: 10.1111/j.1432-1033.1992.tb16769.x [eCite] [Details] Citations: Scopus - 36Web of Science - 37 | |
| 1989 | Halliday GM, Dickinson JL, Muller HK, 'Retinoic acid protests Langerhans' cells from the effects of the tumour promoter 12-O-tetradecanoylphorbol 13-acetate', Immunology, 67, (3) pp. 298-302. ISSN 0019-2805 (1989) [Refereed Article] PMID: 2759656 [eCite] [Details] Citations: Scopus - 10Web of Science - 13 Co-authors: Muller HK |
Chapter in Book
(3 outputs)| Year | Citation | Altmetrics |
|---|---|---|
| 2014 | Nicol D, Chalmers D, McWhirter R, Dickinson J, 'Impressions on the Body, Property and Research', Persons, Parts and Property: How Should We Regulate Human Tissue in the 21st Century?, Hart Publishing Ltd, I Goold, K Greasley, J Herring, L Skene (ed), United Kingdom, pp. 9-23. ISBN 978-1849465465 (2014) [Research Book Chapter] Co-authors: Nicol D; Chalmers D; McWhirter R | |
| 2013 | Chin PS, Dickinson JL, Holloway AF, 'Integrins in Prostate Cancer Invasion and Metastasis', Advances in Prostate Cancer, InTech, Gerhard Hamilton (ed), Croatia, pp. 621-640. ISBN 978-953-51-0932-7 (2013) [Research Book Chapter] DOI: 10.5772/45948 [eCite] [Details] Co-authors: Chin PS; Holloway AF | |
| 2011 | Marthick JR, Holloway AF, Dickinson JL, 'Integrins as determinants of genetic susceptibility, tumour behaviour and their potential as therapeutic targets', Prostate Cancer - From Bench to Bedside, InTech, Philippe E. Spiess (ed), Rijeka, Croatia, pp. 243-266. ISBN 978-953-307-331-6 (2011) [Research Book Chapter] DOI: 10.5772/1285 [eCite] [Details] Co-authors: Marthick JR; Holloway AF |
Conference Publication
(22 outputs)| Year | Citation | Altmetrics |
|---|---|---|
| 2011 | Chin PS, Short AK, West AC, Marthick JR, Holloway AF, et al., 'Regulation of the ITGA2 gene in prostate cancer', Lorne Cancer Conference , February, Lorne, Victoria (2011) [Conference Extract] Co-authors: Chin PS; Short AK; West AC; Marthick JR; Holloway AF | |
| 2011 | Dickinson J, Stankovich J, Thomson R, Tegg E, Marsden K, et al., 'Identification of Susceptibility Genes for Haematological Maligancies', GeneMappers, April, Hobart, Australia (2011) [Conference Extract] Co-authors: Stankovich J; Thomson R; Tegg E; Marsden K; Lowenthal R; Flowers C; Banks A; Piaszczyk A; Foote S | |
| 2011 | Tegg E, Stankovich J, Thomson R, Perera D, Marsden K, et al., 'Whole genome sequencing of CLL case', GeneMappers, April, Hobart, Australia (2011) [Keynote Presentation] Co-authors: Tegg E; Stankovich J; Thomson R; Perera D; Marsden K; Lowenthal R; Flowers C; Banks A; Piaszczyk A; Foote S | |
| 2010 | Koutoulis L, Garry JA, Dickinson JL, Foote SJ, 'Now all I need is a wife', Australasian Research Management Conference , September, Fremantle, Western Australia (2010) [Conference Extract] Co-authors: Koutoulis L; Garry JA; Foote SJ | |
| 2010 | Patterson B, Short A, Polanowski AM, Marthick JR, Thomson R, et al., 'A role for integrin alpha 2 in familial prostate cancer susceptibility', kConFab: Familial Aspects of Cancer: Research and Practice, August, Kingscliff, Queensland (2010) [Conference Extract] Co-authors: Patterson B; Short A; Polanowski AM; Marthick JR; Thomson R; Stankovich J | |
| 2010 | Tegg E, Stankovich J, Thomson R, Perera D, Marsden K, et al., 'Familial Haematological malignancies: The Tasmanian experience', Haematology Society of Australia and New Zealand, Australia and New Zealand Society for Blood Transfusion & Australasian Society for Thrombosis and Homeostasis (2010) [Keynote Presentation] Co-authors: Tegg E; Stankovich J; Thomson R; Perera D; Marsden K; Lowenthal R; Flowers C; Banks A; Piaszczyk A; Foote S | |
| 2009 | Short AK, West AC, Patterson B, Polanowski A, Holloway AF, et al., 'Methylation of the ITGA2 promoter in Prostate Cancer', Epigenetics Conference, Melbourne, Australia (2009) [Conference Extract] Co-authors: Short AK; West AC; Patterson B; Polanowski A; Holloway AF | |
| 2009 | Tegg E, Stankovich J, Thomson R, Perera D, Marsden K, et al., 'Familial Haematological Malignancies', GeneMappers (2009) [Conference Extract] Co-authors: Tegg E; Stankovich J; Thomson R; Perera D; Marsden K; Lowenthal R; Flowers C; Banks A; Piaszczyk A; Foote S | |
| 2008 | Simon KC, Van der Mei IAF, Munger KL, Ponsonby AL, Dickinson JL, et al., 'Smoking as an independent risk factor for multiple sclerosis: considering possible combined effects with the human leukocyte antigen DR15 genotype and anti-EBNA antibody titers', Sage Publications Ltd, 17-20 September, Montreal, Canada, pp. Vol 14 (1) p,200. (2008) [Conference Edited] Co-authors: Van der Mei IAF; Ponsonby AL; Dwyer T | |
| 2008 | Van der Mei IAF, Ponsonby AL, Taylor BVM, Stankovich J, Dickinson JL, et al., 'A potentiation of the adverse effect of human leukocyte antigen-DR15 on the risk of multiple sclerosis by low infant sibling exposure: a population based case-control study', Sage Publications Ltd, 17-20 September, Montreal, Canada, pp. Vol 14 (1) S201-S202. (2008) [Conference Edited] Co-authors: Van der Mei IAF; Taylor BVM; Stankovich J; Foote SJ | |
| 2007 | Perera D, Tegg E, Stankovich J, Thomson R, Silver J, et al., 'Linkage analysis of a large Tasmanian haematological cancer family', GeneMappers (2007) [Conference Extract] Co-authors: Perera D; Tegg E; Stankovich J; Thomson R; Marsden K; Lowenthal R; Flowers C; Banks A; Piaszczyk A; Foote S | |
| 2007 | Tegg E, Stankovich J, Thomson R, Perera D, Marsden K, et al., 'The Tasmanian familial leukaemia and lymphoma research study', Haematology Society of Australia and New Zealand, Australia and New Zealand Society for Blood Transfusion & Australasian Society for Thrombosis and Homeostasis (2007) [Conference Extract] Co-authors: Tegg E; Stankovich J; Thomson R; Perera D; Marsden K; Lowenthal R; Flowers C; Banks A; Piaszczyk A; Foote S | |
| 2007 | Tegg E, Stankovich J, Thomson R, Perera D, Marsden K, et al., 'The Tasmanian familial leukaemia and lymphoma research study', GeneMappers (2007) [Conference Extract] Co-authors: Tegg E; Stankovich J; Thomson R; Perera D; Marsden K; Lowenthal R; Flowers C; Banks A; Piaszczyk A; Foote S | |
| 2006 | Dickinson J, Thomson R, Patterson B, Polanowski A, Stankovich J, et al., 'Prostate Cancer Sun Exposure and Genes Modifying Risk', 11th International Congress of Human Genetics, 6-10th August, Brisbane, Australia (2006) [Conference Extract] Co-authors: Thomson R; Polanowski A; Stankovich J; Fryer J; Blizzard L | |
| 2005 | Dickinson JL, Patterson B, Polanowski A, Thomson R, Dwyer T, et al., 'Prostate Cancer: Sun Exposure and Genes Modifying Risk', American Society of Human Genetics Conference, October, Salt Lake City, Utah (2005) [Conference Extract] Co-authors: Patterson B; Polanowski A; Thomson R; Blizzard L; Fryer J; McKay J | |
| 2005 | Foote SJ, Rubio JP, Bahlo M, Kilpatrick TJ, Speed TP, et al., 'Multiple Sclerosis: a haplotype association study', Novartis Foundation Symposium, 2005, pp. 31-39. (2005) [Conference Extract] Co-authors: Foote SJ; Stankovich J; Taylor BVM; Sale MM; Van der Mei IAF; Groom PS | |
| 2005 | McKay J, Fitzgerald L, Stankovich J, Banks A, Hazelwood K, et al., 'Linkage analysis of a second large prostate cancer family from southern Tasmania, Australia', American Society of Human Genetics Conference, October, Salt Lake City, Utah (2005) [Conference Extract] Co-authors: Fitzgerald L; Stankovich J; Banks A; Hazelwood K | |
| 2001 | Dickinson JL, Wheatley CM, Fitzgerald L, Brown M, Craig JE, et al., 'Investigation of a possible role for the Norrie Disease gene in Retinopathy of Prematurity', Human Genome Society Conference, Cairns, Australia (2001) [Conference Extract] | |
| 2000 | Mackey DA, Green C, Sale MM, Craig JE, Dickinson JL, et al., 'Familial aggregation of glaucoma: Experience with the glaucoma inheritance study in Tasmania (GIST)', The Association for Research in Vision and Ophthalmology, April 30-May 5, 2000, Fort Lauderdale, Florida, pp. S527. (2000) [Conference Extract] Co-authors: Mackey DA; Sale MM; Craig JE; Stanwix SP; McCartney PJ | |
| 2000 | Sale MM, Craig JE, Dickinson JL, Love J, Hanson I, et al., 'Phenotypic variability in a large aniridia pedigree with a novel PAX6 1410delC', The Association for Research in Vision and Ophthalmology, April 30-May 5, 2000, Fort Lauderdale, Florida, pp. S822. (2000) [Conference Extract] Co-authors: Sale MM; Craig JE; Mackey DA | |
| 1998 | Dickinson JL, Mackey DA, Craig JE, McNaught AI, Wilkinson CH, et al., 'Predictive DNA testing for glaucoma with the GLC1A gene: experience with a large Australian family', International Human Genome Conference, Brisbane, Australia (1998) [Conference Extract] | |
| 1995 | Dickinson JL, Antalis TM, 'Evidence that the Active Site and the C-D interhelical region of plasminogen activator inhibitor type 2 are required for protection from TNFa induced apoptosis', Fifth International Workshop on the Molecular and Cellular Biology of Plasminogen Activation, Finland (1995) [Keynote Presentation] |
Grants & Funding
Funding Summary
Number of grants
94
Total funding
$37,450,392
Projects
CNS Cancers Tasmania Program (2024)$97,812
- Description
- To map the genetic and epigenetic changes that drive brain tumour development.
- Funding
- Walter and Eliza Hall Institute of Medical Research ($97,812)
- Scheme
- Contract Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Marshall O; Taberlay PC; Young K; Dickson TC
- Year
- 2024
Exploring the utility of long-read sequencing to determine telomere lengths in peripheral blood in a familial idiopathic pulmonary fibrosis cohort. (2024)$19,485
- Description
- This pilot project aims to explore long-read sequencing as an alternative method to measure the repetitive sequences at the end of chromosomes called telomeres. This method has the potential to reduce logistical challenges, reduce cost and improve the accuracy of the results, with broad implications both in the clinical management of idiopathic pulmonary fibrosis patients as well as patients with other manifestations of inherited telomere biology disorder such as haematological malignancies and bone marrow failure.
- Funding
- Donation via Menzies Institute for Medical Research ($19,485)
- Scheme
- Donation - Individual
- Administered By
- University of Tasmania
- Research Team
- Lucas SE; Nelson N; Marthick J; Vanhaeften R; Blackburn NB; Dickinson JL
- Year
- 2024
Accelerating precision medicine for PF: characterising the high-risk PF genetic landscape (2024 - 2028)$4,409,340
- Description
- Understanding the genes causing inherited disease is revolutionising how we diagnose and treat people with these conditions. The objective of this proposal is to bring these advances to those with devastating inherited fibrotic lung disease by addressing the current critical gaps in our knowledge of the genes involved. This knowledge will provide patients and their health care team with better options for early diagnosis, and improved tailored treatments for this fatal lung disease.
- Funding
- National Health & Medical Research Council ($4,409,340)
- Scheme
- Grant-Ideas
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Lucas SE; Philp A; Mackintosh J; Raspin K; Troy L; Nelson N
- Period
- 2024 - 2028
- Grant Reference
- 2023/GNT2029461
Discovery of Rare Prostate Cancer Risk Variants to Innovate Gene-Based Clinical Tests (2024)$99,894
- Description
- We propose to identify and characterise novel, rare PrCa variants by applying whole genome sequencing to our powerful collection of large Tasmanian PrCa families.
- Funding
- Tour de Cure ($99,894)
- Scheme
- Grant - Senior Research
- Administered By
- University of Tasmania
- Research Team
- FitzGerald LM; Dickinson JL; Raspin K
- Year
- 2024
Bringing Precision in Prostate Cancer Medicine to Tasmania (2024)$30,000
- Description
- In Australia, precision medicine is delivering significant improvements in outcomes for several common cancers, yet such innovation for prostate cancer lags significantly behind, particularly in regional areas like Tasmania. As the prostate cancer clinical space embraces this innovation, it is imperative that we seek engagement from the Tasmanian community in the design of our clinical pathways for effective delivery of genetic information. This project will engage with Tasmanian men diagnosed with prostate cancer, their carers/family members and healthcare providers to identify important and acceptable patient reported outcome measure(s) related to genetic testing, which will allow us to develop tools to aide with the delivery of genetic information in the clinical management of prostate cancer.
- Funding
- Cancer Council of Tasmania ($30,000)
- Scheme
- Grant-Small
- Administered By
- University of Tasmania
- Research Team
- Raspin K; Roydhouse J; Dickinson JL; FitzGerald LM; Nott L; Skala M; Harrup R
- Year
- 2024
CRE for Pulmonary Fibrosis - towards individualised care (2023 - 2027)$2,500,000
- Description
- Interstitial lung disease (ILD) encompasses a group of lung disorders characterised by fibrosis of the lung tissue. Typically ILD patients experience significant impacts on quality of life, and effective treatments are lacking. The most common form idiopathic pulmonary fibrosis is also the most serious with a life expectancy of 2-5 years. This team is at the forefront of international developments prompting a new and individualised approach to care of patients with ILD. Recent advances show there are common underlying genetic and biological pathways, and new anti-fibrotic medications are effective across the whole ILD spectrum. In this CRE-ILD, we bring together a new multidisciplinary, diverse team from across Australia, to address patient-identified research priorities.
- Funding
- National Health & Medical Research Council ($2,500,000)
- Scheme
- Grant-Centre of Research Excellence
- Administered By
- University of Sydney
- Research Team
- Corte T; Holland A; Chambers D; Hansbro P; Dickinson JL; Palmer AJ; Moodley Y; Powell J
- Period
- 2023 - 2027
- Grant Reference
- 2015613
Genomic approaches for better outcomes in PF: addressing the gap. (2023 - 2024)$2,946,131
- Description
- Pulmonary fibrosis (PF) is a typically progressive and fatal lung disease and primarily affect older adults. This rare lung condition has a devastating impact on quality of life, with lung transplant offering the only prospect of significant life extension. Whilst newly approved anti-fibrotic drugs have been shown to slow progression of disease and reduce mortality, patients do not report measurable improvements in quality of life, and frequent complications are associated with their use. Genetic factors strongly underpin the pathogenic pathways leading to inherited forms of PF and while there has been significant progress in the identification of high-risk genetic variants underpinning PF, we still lack the essential functional evidence to establish how these high-risk genetic variants impact pathogenic processes in disease. Moreover, there is a resounding call to better understand how these risk variants interact with environmental risk factors (cigarette smoke and viral to infection) and to this knowledge to define disease endotypes, improve diagnosis, inform patient management and deliver new drug targets. Our multi-disciplinary team will address these critical knowledge gaps by leveraging established well-characterised clinically-annotated genetic resources, innovative stem cell models and established animal models to expand our knowledge of the high risk genes and biological pathways influence pathogenic processes in PF, including the interaction with environmental factors and drug treatments. We will engage with our establish consumer network to devise consumer informed pathways for implementation of genomics into clinical care. The outcomes of our work will facilitate earlier diagnosis, improve genetic diagnosis rate, define new options for targeted treatment, improve patient management and enable better targeting of health care expenditure.
- Funding
- Medical Research Future Fund ($2,946,131)
- Scheme
- Grant - Genomics Health Futures Mission
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Hansbro P; Holland A; Corte T; Lucas SE; Philp A; Powell J; Chambers D; Bryan T; Raspin K; Mackintosh J; Moodley Y; Fairfax KA; Liu G
- Period
- 2023 - 2024
A Clinical and Biospecimens Prostate Cancer Resource for Biomarker Research in Tasmania (2023)$24,943
- Description
- We propose to continue growing our clinical and biospecimens prostate cancer resource. This project aims to collect biological samples from Tasmanian men participating in the Prostate Cancer Outcomes Registry, Tasmania. This valuable clinical and genomic resource will allow important biomarker research into predicting prostate cancer outcomes and improving treatment strategies.
- Funding
- Royal Hobart Hospital Research Foundation ($24,943)
- Scheme
- Grant-Project
- Administered By
- University of Tasmania
- Research Team
- FitzGerald LM; Dickinson JL; Skala M; Donovan S; Harris H; Redwig F
- Year
- 2023
Supporting Australian Brain Cancer Research with an integrated network of platforms (2023)$5,991,219
- Description
- Our existing national consortium, Brain Cancer Biobanking Australia (BCBA; established in 2015), our partners and investigator team, will address these issues by generating infrastructure to create three essential, integrated Australian-First platforms: Aim 1. An Australian Brain Cancer Registry (ABCR) to identify and address unwarranted variation in clinical practice, ensuring every patient receives the best possible care. Aim 2. An Australian Registry Trials and Patient Enrolment Platform to enable cost effective clinical trials, enhance patient access to affordable cutting-edge treatments, and improve researcher access to patient data. Aim 3. An Australian Biobanking and Organoid Platform to standardise national brain cancer biobanking, facilitate linkage of ABCR data to banked samples, and establish national protocols for brain organoid development and screening pipelines to advance translational research.
- Funding
- Medical Research Future Fund ($5,991,219)
- Scheme
- Grant - Aus Brain Cancer Research Infrastructure
- Administered By
- University of Tasmania
- Research Team
- Jeffree R; Dickinson JL; Harrup R
- Year
- 2023
Closing the Health Gap: Precision Care for Men with Prostate Cancer (PC4PC-TAS) (2023 - 2025)$448,222
- Description
- In Australia, precision medicine is delivering significant improvements in outcomes for several common cancers, yet such innovation for prostate cancer (PrCa) lags significantly behind, particularly in regional areas like Tasmania. This study will undertake the consumer-focused work necessary to design and deliver patient-centred genomic medicine in PrCa. This will ensure we are able predict men at risk of developing aggressive PrCa and identify those men eligible for gene-based therapies.
- Funding
- Royal Hobart Hospital Research Foundation ($448,222)
- Scheme
- Grant-Major Project
- Administered By
- University of Tasmania
- Research Team
- Raspin K; Dickinson JL; Roydhouse J; Wallis M; Lucas SE; FitzGerald LM; Harrup R; Skala M; Nott L
- Period
- 2023 - 2025
Identifying key drivers of metastatic bone lesions from several cancer types. (2023)$13,900
- Description
- Once cancers have spread, they become difficult to treat and increasingly resistant to therapy. Consequently, survival rates plummet, particularly for those with bone metastases. In this proposal, we aim to identify key changes between primary tumours and metastatic bone tumours in patients who have gone on to develop secondary cancer. This will allow us to identify the underlying reasons as to why some patients develop secondary cancers and others do not.
- Funding
- Cancer Council of Tasmania ($13,900)
- Scheme
- Grant-Small
- Administered By
- University of Tasmania
- Research Team
- Raspin K; Dickinson JL; FitzGerald LM; Nott L
- Year
- 2023
Explaining high risk gene/variant function in IPF (2022)$159,540
- Description
- This is follow-up research to the current GRIPF project, which is identifying rare, high risk familial IPF genes. It will help explain how these genes cause disease, drive disease progression and whether there are opportunities to target these genes for therapies.
- Funding
- Private Foundation ($159,540)
- Scheme
- Donation - Institutional
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Zosky GR; Lucas SE; Raspin K; Corte T; Powell J
- Year
- 2022
Precision Medicine for Men with Prostate Cancer (2022)$21,142
- Description
- Precision medicine and the burgeoning use of complex genetic data to inform clinical management of cancer is here. As Tasmania embraces this innovation, it is imperative that we seek engagement from the Tasmanian community in the design of our clinical pathways for delivery.
- Funding
- Royal Hobart Hospital Research Foundation ($21,142)
- Scheme
- Grant-Project
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Roydhouse J; Raspin K; FitzGerald LM; Harrup R; Nott L; Wallis M
- Year
- 2022
Advancing Precision Medicine for Families with Haematological Malignancy (2022)$22,942
- Description
- The aim of this project is to recruit Tasmanian families that have three or more close relatives with blood cancer or a related disorder. Whole genome sequencing will be performed with the aim of identifying genes underpinning the development of blood cancers. This project builds on the existing Familial Haematological Malignancy Project.
- Funding
- Royal Hobart Hospital Research Foundation ($22,942)
- Scheme
- Grant-Project
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Nelson N; Lucas SE; Fairfax KA; Harrup R
- Year
- 2022
Understanding TMPRSS2:ERG gene fusions to improve prostate cancer diagnosis and treatment options (2022)$24,776
- Description
- This project aims to understand the impact the TMPRSS2:ERG fusion has on prostate cancer in the Tasmanian population. To do this we will determine the frequency of this fusion in our population and determine its association with clinicopathological features of prostate cancer.
- Funding
- Cancer Council of Tasmania ($24,776)
- Scheme
- Grant-Small
- Administered By
- University of Tasmania
- Research Team
- FitzGerald LM; Dickinson JL; Raspin K
- Year
- 2022
CNS Tumour Biobank for Tasmanians (2022)$18,750
- Description
- Collect tumour samples for biobanking
- Funding
- Royal Hobart Hospital Research Foundation ($18,750)
- Scheme
- Grant-Project
- Administered By
- Tasmanian Health Service
- Research Team
- Harrup R; Dickinson JL
- Year
- 2022
DNA Damage Repair Gene Variants in Clinically Significant Prostate Cancer (2021)$9,608
- Description
- Genetic study to identify key mutations underpinning aggressive PrCa.
- Funding
- Cancer Council of Tasmania ($9,608)
- Scheme
- Grant-Small
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; FitzGerald LM
- Year
- 2021
Utilising large Tasmanian families to determine the impact of rare genetic variation on prostate cancer. (2021 - 2023)$349,920
- Description
- This project aims to identify rare genetic changes that increase the chance of developing prostate cancer. To do this, we will apply cutting-edge technologies to a large Tasmanian familial prostate cancer resource comprising both germline (e.g. blood) and tumour samples.
- Funding
- Royal Hobart Hospital Research Foundation ($349,920)
- Scheme
- Grant - Williams Oncology
- Administered By
- University of Tasmania
- Research Team
- FitzGerald LM; Dickinson JL; Skala M; Donovan S; Redwig F
- Period
- 2021 - 2023
Advancing Precision Medicine for Men Diagnosed with Prostate Cancer (2021)$10,470
- Description
- Genetic study to identify key mutations underpinning aggressive PrCa.
- Funding
- Perpetual Trustees ($10,470)
- Scheme
- CF - Betty Lowe Memorial
- Administered By
- University of Tasmania
- Research Team
- Raspin K; Dickinson JL; FitzGerald LM; Marthick JR
- Year
- 2021
Applying innovative 'omics' technologies to identify key molecular drivers of metastatic bone tumours (2021)$14,778
- Description
- Once cancers have spread, they become difficult to treat and increasingly resistant to therapy. Consequently, survival rates plummet, particularly for those with bone metastases. Using cutting-edge technologies, we have identified key changes in genes that allow metastatic tumour cells to survive in bone. We aim to characterise the metastatic capabilities of these key changes and determine their value as prognostic/therapeutic targets.
- Funding
- Cancer Council of Tasmania ($14,778)
- Scheme
- Grant-Small
- Administered By
- University of Tasmania
- Research Team
- Raspin K; Dickinson JL; FitzGerald LM; Holloway AF
- Year
- 2021
The TELO-SCOPE Study: Attenuating Telomere Attrition with Danazol. Is there Scope to Improve Outcomes in Pulmonary Fibrosis? (2020 - 2024)$1,828,443
- Description
- The TELO-SCOPE study will be a world-first, multi-centre, randomised, placebo-controlled trial (RCT) evaluating the efficacy and safety of the synthetic androgen danazol in participants with PF and short (< 10th centile) age-adjusted telomere length (PF-ST).
- Funding
- Medical Research Future Fund ($1,828,443)
- Scheme
- Grant - Rare Cancers, Rare Diseases and Unmet Need
- Administered By
- University of Queensland
- Research Team
- Chambers D; Dickinson JL
- Period
- 2020 - 2024
Gaining new insights into metastatic bone tumours (2020)$24,925
- Description
- Molecular analysis of prostate cancer tumour specimen to identify new molecular targets for therapy.
- Funding
- Royal Hobart Hospital Research Foundation ($24,925)
- Scheme
- Grant-Project
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Holloway AF; Nott LM; Liu G; FitzGerald LM; Brettingham-Moore KH; Hewitt A; Taberlay PC
- Year
- 2020
A Clinical and Biospecimens Prostate Cancer Resource for Biomarker Research in Tasmania (2020)$22,664
- Description
- We propose to continue growing our clinical and biospecimens prostate cancer resource. This project aims to collect biological samples from Tasmanian men participating in the Prostate Cancer Outcomes Registry, Tasmania. This valuable clinical and genomic resource will allow important biomarker research into predicting prostate cancer outcomes and improving treatment strategies.
- Funding
- Royal Hobart Hospital Research Foundation ($22,664)
- Scheme
- Grant-Project
- Administered By
- University of Tasmania
- Research Team
- FitzGerald LM; Dickinson JL; Jones M; Donovan S; Murdolo V; Redwig F
- Year
- 2020
Genetic Research in Idiopathic Pulmonary Fibrosis (GRIPF) Study: A case-control cohort enriched for genetic disease (2020 - 2021)$102,800
- Description
- Idiopathic pulmonary fibrosis (IPF) is a severe and progressive lung disease characterised by fibrosis of the lungs. IPF has a strong genetic basis. Identifying the underpinning genetics of IPF is the essential first step in developing much needed therapies. It will also aid early diagnosis and improve patient management, which will reduce patients' reliance on the healthcare system, improve their quality of life, and reduce the economic burden of pulmonary fibrosis.Genetic studies in families with multiple cases of disease are a powerful approach to identify causative genes, however, few such studies have been conducted in IPF. This project aims to fill this gap by establishing a cohort of IPF cases with a family history of disease and healthy, unrelated controls with extensive clinical data and blood/saliva samples. Future genetic analysis of these individuals will assist in identifying genes involved in IPF, complementing existing work that is already underway.
- Funding
- Perpetual Trustees ($102,800)
- Scheme
- Grant-Trust Fund
- Administered By
- University of Tasmania
- Research Team
- Lucas SE; Dickinson JL
- Period
- 2020 - 2021
Select Foundation Senior Research Fellowship - Cancer (2019 - 2022)$375,000
- Funding
- The Select Foundation ($375,000)
- Scheme
- Fellowship-Senior Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL
- Period
- 2019 - 2022
Is EEF2 a potential biomarker for more aggressive prostate cancer in Tasmanian patients? (2019)$23,906
- Description
- A recent study suggests that higher EEF2 levels are associated with more aggressive prostate cancer, however these results are yet to be validated. We aim to validate these results in our Tasmanian prostate cancer resource and determine if higher EEF2 levels are caused by DNA abnormalities in the tumour.
- Funding
- Royal Hobart Hospital Research Foundation ($23,906)
- Scheme
- Grant-Project
- Administered By
- University of Tasmania
- Research Team
- FitzGerald LM; Dickinson JL; Murdolo V; Donovan S; Malley RC; Redwig F
- Year
- 2019
Human health and the aerial microbiome: uncovering interactions across Australia (2019)$19,989
- Description
- This is a pilot project for a Category 1 funding application in 2020. It includes two core activities: (1) Holding a workshop to develop collaborations and methodologies; and (2) A pilot personal monitoring study collecting paired aerial microbiome and health symptom data from volunteers.
- Funding
- University of Tasmania ($19,989)
- Scheme
- Grant-Research Enhancement Program
- Administered By
- University of Tasmania
- Research Team
- Jones PJ; Johnston F; Dickinson JL; Flies E
- Year
- 2019
Identifying the Underlying Genetic Drivers of IPF using Complementary Approaches (2018 - 2024)$1,481,558
- Description
- In the first instance the goal is to define the contribution of genetic variants to IPF in the Australian population, and we are in a unique position in Australia through our collaboration with Professor Schwartz. Our focus in this particular project is on rare genetic variation, and whilst it is likely that common variation will be similar to other mostly Caucasian populations there are likely to be differences in the rare variants in genes contributing to disease in the different populations. It is therefore important that these types of studies are performed in our population if we are going to understand the biology of disease in our patients. As discussed the identification of rare variants underpinning complex disease is proving fruitful both in understanding the biology of disease, the spectrum of clinical manifestations observed and importantly providing new potential targets for therapy.
- Funding
- Lung Foundation Australia ($1,481,558)
- Scheme
- Contract Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Corte T; Holloway AF; Charlesworth JC; Walters EH; Wood-Baker R
- Period
- 2018 - 2024
Targeting Lin28 for the control of the most aggressive subgroups of medulloblastoma (2018)$24,938
- Funding
- University of Tasmania ($24,938)
- Scheme
- Grant- Research Enhancement Program
- Administered By
- University of Tasmania
- Research Team
- Azimi I; Guven N; Dickinson JL
- Year
- 2018
Genetics in Regional Healthcare: Addressing Access and Disparities in the Implementation of Genetic Medicine in Regional Healthcare (2018)$9,974
- Description
- The National Health Genomics Policy Framework was released in 2018 with the goal being the development of a collaborative and co-ordinated approach to integrate genomics into the delivery of healthcare in Australia. A recognised and significant challenge is how to deliver this in the most efficient, equitable, and effective way in regional and rural sectors where there are recognised unique challenges distinct from those in our larger metropolitan tertiary healthcare settings. Integration of genomics into healthcare provision will impact all subacute chronic conditions with specific implications for education and prevention, selection of effective therapies, patient management and ongoing followup. Although there are multiple areas to tackle in the implementation of the National Genomics framework, one of the key undertakings will be to address the needs of the healthcare workforce and their engagement in the development of appropriate pathways for delivery. Genetics and genomics is set to become integral to the management of all health conditions, with many aspects deliverable in the sub-acute sector.
- Funding
- University of Tasmania ($9,974)
- Scheme
- Grant- Research Enhancement Program
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Canny B; Nicol D; Critchley C; Presser J; Williamson J; Burke JM
- Year
- 2018
A Clinical and Biospecimens Prostate Cancer Resource for Biomarker Research in Tasmania (2018)$22,146
- Description
- We propose to build upon the clinically-focused Prostate Cancer Outcomes Registry, Tasmania (PCOR-TAS) and collect matched biological samples to create a valuable resource for both clinicians and scientists. The availability of clinical and genetic data will allow important biomarker research into predicting prostate cancer outcomes and improving treatment strategies.
- Funding
- Royal Hobart Hospital Research Foundation ($22,146)
- Scheme
- Grant-Minor Project
- Administered By
- University of Tasmania
- Research Team
- FitzGerald LM; Dickinson JL; Skala M; Stokes BC; Donovan S; Malley RC; Redwig F; Holloway AF; Taberlay PC
- Year
- 2018
A Clinical and Biospecimens Prostate Cancer Resource for Biomarker Research in Tasmania (2018)$24,926
- Description
- We propose to build upon the clinically-focused Prostate Cancer Outcomes Registry, Tasmania (PCOR-TAS) and collect matched biological samples to create a valuable resource for both clinicians and scientists. The availability of clinical and genetic data will allow important biomarker research into predicting prostate cancer outcomes and improving treatment strategies.
- Funding
- Cancer Council of Tasmania ($24,926)
- Scheme
- Grant-Small
- Administered By
- University of Tasmania
- Research Team
- FitzGerald LM; Dickinson JL; Skala M; Donovan S
- Year
- 2018
Inherited genes in prostate cancer: addressing the gaps in our understanding (2018)$24,933
- Description
- Prostate cancer (PrCa) is the most commonly diagnosed cancer in Australian men, aside from non-melanoma skin cancer. More than 18,000 men are diagnosed annually and many more live with this cancer, which is increasingly being considered a chronic disease. Furthermore, over 3,000 men die each year from this disease. Today we are still unable to distinguish at diagnosis indolent cancers from those that are likely to progress to metastatic disease. Treatment options remain limited, with surgical, chemical castration and radiological options all associated with significant side effects. Further, once the cancer has spread beyond the prostate to distant sites such as the bone, five-year survival rates plummet to less than 10%. At present, we remain reliant on the prostate specific antigen (PSA) test for PrCa screening, the value of which is widely debated. It is reported that for every 1,000 men screened, 110 are accurately diagnosed but over 50 of these men suffer complications from treatment. In addition, there will be over 100 false positives, with five men dying despite screening, and just one death avoided.One of the strongest risk factors for this disease is family history, indeed PrCa is reported to have the highest heritability of any cancer. An early focus of genetic research has been to identify risk variants that are relatively common in the population. While these studies successfully identified over 160 common risk variants, it is now clear that these only explain a small proportion of inherited risk. More recently, it has become evident that rare genetic risk variants have a far greater and more clinically relevant effect on disease risk. Importantly, rare variants are providing greater insights into cancer risk and proving to be useful drug targets for new therapies (e.g. rare DNA repair gene variants can be targeted with PARP inhibitors).Our NHMRC research proposal aims to apply recently available technologies and a family-based approach to identify rare variants contributing to PrCa and to determine the impact of these variants on gene function and role in disease. Results from our proposal will provide much needed insight into the mechanism by which these variants increase PrCa risk, and move these discoveries into the clinic through integration into clinical care models. Importantly, our approach utilises the niche advantages of the Tasmanian population combined with national and international expertise and resources from Professor Roger Reddel (Children's Medical Research Institute, Sydney), Professor Janet Stanford (Fred Hutchinson Cancer Research Center, Seattle), and Assistant Professor Brian Helfand (Northshore Hospital, Chicago).
- Funding
- University of Tasmania ($24,933)
- Scheme
- Grant- Research Enhancement Program
- Administered By
- University of Tasmania
- Research Team
- FitzGerald LM; Dickinson JL; Helfand B
- Year
- 2018
Integrated Biomarker Discovery and Tissue Banking Facility (2018)$1,174,000
- Description
- Establishment of an integrated biomarker discovery and tissue bank facility at the Medical Sciences Precinct, University of Tasamania. This facility will include biomarker analyser and validation systems, high-throughput qPCR machines, a genealogical and biospecimen management system and a managed tissue bank.
- Funding
- University of Tasmania ($1,174,000)
- Scheme
- null
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; King AE
- Year
- 2018
Investigation of chromosomal loss and gain at 7p21 in a Tasmanian hereditary prostate cancer family (2017)$23,186
- Description
- This project aims to fine-map and determine the underlying cause of chromosomal loss and gain at 7p21 in a Tasmanian hereditary prostate cancer family. This region contains a candidate gene, ETV1, which is known to be translocated in ~7% of tumours and increases the invasive and metastatic potential of tumours. Emerging therapies targeting this translocation could improve outcomes in Tasmanian men with prostate cancer.
- Funding
- Royal Hobart Hospital Research Foundation ($23,186)
- Scheme
- Grant-Establishment
- Administered By
- University of Tasmania
- Research Team
- FitzGerald LM; Dickinson JL; Malley RC; Donovan S; Dun K; Diano G; Skala M; Redwig F
- Year
- 2017
Developing CRISPR/Cas Library Screens for identifying Novel Cancer Therapies (2017)$63,845
- Description
- Our understanding of many cancers has improved dramatically over the past decade predominantly due to our ability to sequence entire genomes, at scale. Yet, we still require a better understanding of the underlying mechanisms that initiate and perpetuate cancers, as well as gene-based factors that initiate the transition from indolent to aggressive cancers with a propensity to metastasize. CRISPR/Cas is proving a robust, powerful and necessary tool in the laboratory that will undoubtedly underpin the next breakthrough in the field of cancer. As such, it is essential that we develop this capability at the University of Tasmania in a timely manner.The specific AIMS of this proposal are to:Aim 1: Establish CRISPR/Cas screening at the University of Tasmania as a tool to identify genesthat drive aggressive and metastatic cancers.Aim 2: Perform a genome-wide CRISPR/Cas negative selection (loss-of-function) screen toidentify genes essential for proliferation and survival, as well as metastatic behaviour.
- Funding
- University of Tasmania Foundation Inc ($63,845)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Taberlay PC; Hewitt A; Holloway AF; Liu G; Dickinson JL; Brettingham-Moore KH; Fitzgerald L; Eri RD; Cook AL
- Year
- 2017
David Collins Leukaemia Foundation Elite Research Scholarship - Epigenetic and Transcriptional regulation of leukaemia (2016 - 2019)$153,000
- Description
- This project will investigate how epigenetic and transcription factors co-operate to control gene expression, how this is reprogrammed in leukaemia and how epigenetic drugs impact these gene expression programs.
- Funding
- David Collins Leukaemia Foundation ($153,000)
- Scheme
- Donation - Individual
- Administered By
- University of Tasmania
- Research Team
- Holloway AF; Dickinson JL; Brettingham-Moore KH
- Period
- 2016 - 2019
Molecular biomarkers for seabird age estimation (2016)$800
- Description
- The aim of my research is to develop and implement a non-lethal method to accurately and reliably estimate the age of individual long-lived seabirds.
- Funding
- Linnean Society of New South Wales ($800)
- Scheme
- Grant-Joyce W Vickery Scientific Research Fund
- Administered By
- University of Tasmania
- Research Team
- Hindell MA; McMahon CR; Dickinson JL; Jarman SN; De Paoli-Iseppi R
- Year
- 2016
Molecular biomarkers for seabird age estimation. (2016)$7,500
- Description
- The aim of my research is to develop and implement a non-lethal method to accurately and reliably estimate the age of individual long-lived seabirds.
- Funding
- Holsworth Wildlife Research Endowment ($7,500)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Hindell MA; Dickinson JL; McMahon CR; Jarman SN; Deagle BE; De Paoli-Iseppi R
- Year
- 2016
DNA sequencer for genetic research (2015)$80,000
- Description
- Purchase of a 3500 Genetic Analyzer for the sequencing of DNA to support genetic and molecular research.
- Funding
- Ian Potter Foundation ($80,000)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Burdon KP; Dickinson JL
- Year
- 2015
Tasmanian Genetic Research in Inherited Disease (TasGRID) (2015 - 2016)$200,000
- Description
- The aim of this project is to generate "genomics hub" building on current research expertise, laboratory facilities, analytical capabilities, by providing a co-ordinated administration hub and core genomics reference resource. The Menzies has a strategic focus on utilising the unique features of the Tasmanian population for health research Including genomlcs to address the burden of disease in Tasmania. A/Prof Dickinson's team has attracted nationally competitive funding to build expertise, bioinformatics analysis skills in genomics, a laboratory facility equipped with next generation sequencing technology and a computing facility. The funding requested will address two immediate needs *a "genomics hub" co-ordinator, and*a Tasmanian reference genome database.This will facilitate expansion of genomics research in Tasmania, by providing the necessary foundation for leveraging external funding, providing world-class training opportunities for students and importantly will position the University to keep pace internationally in the field of genomics.
- Funding
- University of Tasmania ($200,000)
- Scheme
- Grant-Strategic Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Burdon KP; Charlesworth JC; Chalmers DRC; Nicol D; Maxwell-Stewart HJ
- Period
- 2015 - 2016
Epigenetic regulation of inegrin beta 4 as a predictor of prostate cancer progression (2015)$14,750
- Description
- Prostate cancer diagnoses continue to rise rapidly in Australia, but of most concern is ourcurrent inability to distinguish aggressive tumours with propensity to metastasize from moreindolent disease. This results in unnecessary treatment of many men whose cancer may neverprogress to clinically significant disease. However, progression of the disease results in aggressive, metastatic tumours which are difficult to treat and are associated with poor prognosis. We thus urgently require a better understanding of the underlying drivers of this disease, and particularly the factors and mechanisms that drive the transition to more aggressive tumours with a propensity to spread. These factors may represent biomarkers and potential therapeutic targets in prostate cancer progression.The aims of this study are therefore:1.To determine whether epigenetic changes at the ITGB4 gene are associated with its increased expression in prostate cancer progression, and 2. To investigate whether epigenetic changes at the ITGB4 gene in prostate cancer are driven by the RUNX transcription factors.
- Funding
- Cancer Council of Tasmania ($14,750)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Holloway AF; Dickinson JL; Brettingham-Moore KH; Rao S; Black A
- Year
- 2015
A vulvar cancer cluster caused by genetic susceptibility: investigating the genetic mechanism (2014 - 2016)$1,116,905
- Description
- Cancer of the vulva is 70 times more common in young Aboriginal women in Arnhem Land than in other women. Human Papillomavirus (HPV), which also causes cervical cancer, is the usual cause of this cancer; initial investigations have found that HPV is present in these cancers but is not the reason for the excessive incidence. This study will investigate inherited risk factors contributing to the development of this diseasein this population.
- Funding
- National Health & Medical Research Council ($1,116,905)
- Scheme
- Grant-Project
- Administered By
- Menzies School of Health Research
- Research Team
- Condon J; Dickinson JL; McWhirter R; Rumbold A; Thomson RJ; Boyle J; Garvey G; Markey P
- Period
- 2014 - 2016
- Grant Reference
- 1060187
Familial Haematological Malignancies: understanding the role of inherited causative factors (2014)$20,000
- Description
- Genetic factors are known to contribute to the risk of developing haematological malignancies, however to date the underlying genetic drivers of disease development remain largely unknown. Knowing the causative genes is not only important in understanding the disease process but also provides a range of benefits in the diagnosis, development of tailored treatments, and identification of new targets for therapy. Studying families with multiple cases of these diseases is a powerful approach used to identify the causative genes.
- Funding
- Cancer Council of Tasmania ($20,000)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Charlesworth JC; Foote SJ; Thomson RJ; Holloway AF; Lowenthal RM
- Year
- 2014
Intersection of RUNX and integrin families in leukaemia (2014 - 2015)$30,000
- Funding
- David Collins Leukaemia Foundation ($30,000)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Holloway AF; Dickinson JL
- Period
- 2014 - 2015
The role of epigenetic changes in the progression of clinical disease in Multiple Endocrine Neoplasia Type 1 (MEN 1) (2013)$22,500
- Funding
- Royal Hobart Hospital Research Foundation ($22,500)
- Scheme
- Grant-Research
- Administered By
- University of Tasmania
- Research Team
- Burgess JR; Prentice L; Holloway AF; Dickinson JL
- Year
- 2013
Combining deep sequencing and linkage approaches to identify rare variants contributing to familial prostate cancers (2013 - 2014)$35,000
- Funding
- Cancer Council of Tasmania ($35,000)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Thomson RJ; Charlesworth JC; Holloway AF; Jarman SN
- Period
- 2013 - 2014
Genetic aetiology of familial haematological malignancies (2013 - 2014)$35,000
- Description
- The project outlines the genetic analysis of a rare resource, utilising high density SNP genotyping to perform familial linkage analysis of twelve large families. It will identify genes predisposing to haematological malignancies in a novel dataset.
- Funding
- Cancer Council of Tasmania ($35,000)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Charlesworth JC; Thomson RJ; Lowenthal RM
- Period
- 2013 - 2014
Regulation of integrins by RUNX1 in leukaemia (2013)$30,000
- Funding
- David Collins Leukaemia Foundation ($30,000)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Holloway AF; Dickinson JL; Brettingham-Moore KH
- Year
- 2013
Regulation of Integrin Gene Expression Programs by RUNX in Cancer (2013 - 2016)$26,250
- Description
- The incidence of leukaemia continues to increase in Tasmania despite advances in our understanding and treatment of the disease. A gene which is often disrupted in leukaemia is a master regulator called RUNX1, which controls how and when other genes are switched on in blood cells. This project hypothesises that RUNX1 controls cell surface molecules called integrins. It proposes that disruption of RUNX1 in blood cells leads to the development of leukaemia by altering the integrins on the surface of the cells.
- Funding
- Cancer Council of Tasmania ($26,250)
- Scheme
- Scholarship-PhD Top-Up Grant
- Administered By
- University of Tasmania
- Research Team
- Holloway AF; Dickinson JL
- Period
- 2013 - 2016
Role of NF-kB in radiosensitivity and resistance in prostate cancer (2012)$19,200
- Funding
- Cancer Council of Tasmania ($19,200)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Brettingham-Moore KH; Dickinson JL; Skala M
- Year
- 2012
Prostate cancer risk variants in integrin genes & their role in prostate cancer development (2012)$49,362
- Funding
- Cancer Council of Tasmania ($49,362)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Holloway AF; McMorran BJ; Thomson RJ
- Year
- 2012
Identifying inherited factors underlying familial haematological malignancies (2012)$49,362
- Funding
- David Collins Leukaemia Foundation ($49,362)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Stankovich J; Charlesworth JC; Lowenthal RM; Marsden KA; Tegg EM
- Year
- 2012
Inherited determinants of Cancer Aetiology (2012 - 2016)$644,028
- Description
- Family history of cancer is a strong risk factor for many cancers. Whilst very significant advances have been made in our understanding of common genetic variations contributing to cancer risk, the genetic factors contributing to the inherited portion of cancer risk and those factors influencing disease course remain poorly understood. Current opinion is that the study of families with multiple cases of inherited disease will be a fruitful, alternative approach to gene discovery in human complex disease. This project aims to identify those genetic factors contributing to familial cancer risk and disease course utilising the Tasmanian Familial Cancer Genetics Resources established at the Menzies Research Institute Tasmania.
- Funding
- Australian Research Council ($644,028)
- Scheme
- Fellowship-Future
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL
- Period
- 2012 - 2016
- Grant Reference
- FT120100623
A vulvar cancer cluster in young Indigenous women in Arnhem Land: investigation of community knowledge, genetic susceptibility and supportive care response (2011 - 2012)$692,042
- Funding
- National Health & Medical Research Council ($692,042)
- Scheme
- Grant-Project
- Administered By
- Menzies School of Health Research
- Research Team
- Condon J; McGrath Pam; Rumbold A; Davy M; Tabrizi S; Jamieson S; Taylor-Thomson D; Dickinson JL; Thomson RJ
- Period
- 2011 - 2012
- Grant Reference
- 1003817
Epigenomics of familial prostate cancer (2011)$14,000
- Funding
- Cancer Council of Tasmania ($14,000)
- Scheme
- Grant-Small
- Administered By
- University of Tasmania
- Research Team
- Charlesworth JC; Holloway AF; Dickinson JL
- Year
- 2011
Prostate cancer risk variants in integrin genes and their role in tumour development (2011)$10,000
- Funding
- Cancer Council of Tasmania ($10,000)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Holloway AF; McMorran BJ; Patterson B; Thomson RJ
- Year
- 2011
Epigenetic Regulation of the integrin, ITGA2, in Tumour Development (2011)$10,000
- Funding
- Cancer Council of Tasmania ($10,000)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Holloway AF
- Year
- 2011
Identification of susceptibility genes for familial haematological malignancies (2011)$91,224
- Funding
- Leukaemia Foundation ($91,224)
- Scheme
- Grant-In-Aid
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Foote SJ; Stankovich J; Lowenthal RM; Thomson RJ; Tegg EM; Charlesworth JC; Marsden KA
- Year
- 2011
Transcriptome analysis for predicting response to radiotherapy in prostate cancer patients (2011)$9,091
- Funding
- Royal Hobart Hospital Research Foundation ($9,091)
- Scheme
- Grant-Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Brettingham-Moore KH; Skala M; Holloway AF; Stankovich J
- Year
- 2011
Tasmanian familial haematological malignancy research study (2011)$50,000
- Funding
- Pfizer ($50,000)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Tegg EM; Lowenthal RM; Foote SJ; Dickinson JL; Thomson RJ; Stankovich J; Marsden KA
- Year
- 2011
ITGA2: characterisation as a potential biomarker in prostate cancer (2010)$48,125
- Funding
- Cancer Council of Tasmania ($48,125)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Holloway AF; Patterson B; Stankovich J; McMorran BJ
- Year
- 2010
Identification of susceptibility genes for haematological malignancies (2010)$35,000
- Funding
- David Collins Leukaemia Foundation ($35,000)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Foote SJ; Stankovich J; Lowenthal RM; Thomson RJ; Bahlo M; Marsden KA
- Year
- 2010
Tasmanian genealogical and genetic resource for cancer research (2010)$49,434
- Funding
- Tasmanian Community Fund ($49,434)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL
- Year
- 2010
Elucidation of the role of the integrin alpha 2 gene (ITGA2) in prostate cancer (2009)$45,600
- Funding
- Cancer Council of Tasmania ($45,600)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Holloway AF; Patterson B; Stankovich J; McMorran BJ
- Year
- 2009
Investigating the genetics of familial haematological cancers in Tasmania (2009)$29,132
- Funding
- David Collins Leukaemia Foundation ($29,132)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Foote SJ; Tegg EM; Stankovich J; Lowenthal RM; Marsden KA; Thomson RJ; Bahlo M
- Year
- 2009
Integrative genomic approaches to understanding the genetics of prostate cancer (2009 - 2011)$515,699
- Description
- The aims of this project are to: 1) examine the contribution of 14 recently identified prostate cancer susceptibility loci to risk of disease in the Tasmanian Familial and Sporadic Prostate Cancer datasets; 2) perform genome-wide linkage analysis of selected large families with an increased incidence of prostate cancer to identify new cancer susceptibility loci; 3) examine these loci in the context of the results obtained from Aims 1-3; 4) prioritise genes lying within candidate intervals using a variety of expression and genomic techniques alongside bioinformatic approaches; and 5) continue to expand the Tasmanian Prostate Cancer Dataset using Tasmanian Cancer Registry records and the Menzies Genealogical Database.
- Funding
- Cancer Australia ($515,699)
- Scheme
- Grant-Priority-driven Collab. Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Foote SJ; Charlesworth JC; Thomson RJ; Bahlo M
- Period
- 2009 - 2011
Elucidation of the role of a novel susceptibility gene in prostate cancer (2008)$25,000
- Funding
- Cancer Council of Tasmania ($25,000)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Holloway AF; Patterson B; McMorran BJ; Stankovich J
- Year
- 2008
Development of the Tasmanian Familial Prostate Cancer Genetic Resource (2008)$76,588
- Funding
- Tasmanian Community Fund ($76,588)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL
- Year
- 2008
Investigating the genetics of familial haematological cancers in Tasmania (2008)$25,000
- Funding
- David Collins Leukaemia Foundation ($25,000)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Foote SJ; Stankovich J; Lowenthal RM; Marsden KA; Bahlo M
- Year
- 2008
Elucidation of the role of a novel susceptibility gene in prostate cancer (2008)$25,000
- Funding
- Royal Hobart Hospital Research Foundation ($25,000)
- Scheme
- Grant-Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Holloway AF; Patterson B; McMorran BJ; Stankovich J
- Year
- 2008
Genetic and Bioinformatic Analysis of Complex Human Diseases (2008 - 2012)$8,134,805
- Funding
- National Health & Medical Research Council ($8,134,805)
- Scheme
- Grant-Program
- Administered By
- University of Tasmania
- Research Team
- Foote SJ; Speed TP; Smyth G; Bahlo M; Chalmers DRC; Amor D; Dickinson JL
- Period
- 2008 - 2012
- Grant Reference
- 490037
Investigating the genetics of familial haematological cancers in Tasmania (2007)$60,000
- Funding
- Cancer Council of Tasmania ($60,000)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Stankovich J; Lowenthal RM; Marsden KA; Patterson B; Quinn SJ
- Year
- 2007
The ACRF Tasmanian Inherited Cancer Centre (ATICC) (2007 - 2009)$1,100,000
- Funding
- Australian Cancer Research Foundation ($1,100,000)
- Scheme
- Grant-Research
- Administered By
- University of Tasmania
- Research Team
- Foote SJ; Venn A; Lowenthal RM; Vickers JC; Dickinson JL; Blizzard CL; Stankovich J; Bahlo M; Chalmers DRC
- Period
- 2007 - 2009
The Tasmanian Leukaemia and Other Haematopoietic Malignancies Research Study (2006)$40,000
- Funding
- Perpetual Trustees ($40,000)
- Scheme
- Grant-Trust Fund
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Foote SJ
- Year
- 2006
The Tasmanian prostate cancer genetics study (2006 - 2011)$148,500
- Funding
- Max Bruce Trust ($148,500)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL
- Period
- 2006 - 2011
Identification of Genes that Influence MS Progression by Pathways that Involve UV Exposure: a Prospective Cohort Study (2006 - 2007)$100,000
- Funding
- Ian Potter Foundation ($100,000)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- van der Mei IAF; Foote SJ; Dickinson JL; Ponsonby AL; Taylor BVM; Dwyer T; Blizzard CL
- Period
- 2006 - 2007
Cancer Council Tasmania, Research Fellow (2006 - 2010)$460,000
- Funding
- Cancer Council of Tasmania ($460,000)
- Scheme
- Fellowship
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL
- Period
- 2006 - 2010
Sanyo Upright Freezer (2006)$18,590
- Funding
- National Health & Medical Research Council ($18,590)
- Scheme
- Grant-Equipment
- Administered By
- University of Tasmania
- Research Team
- Venn A; Foote SJ; Dickinson JL; Jones G
- Year
- 2006
- Grant Reference
- 361670
Study of Molecular Events in Large Tasmanian Prostate Cancer Families (2005)$20,000
- Funding
- Cancer Council of Tasmania ($20,000)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; McKay JD; Venter DJ
- Year
- 2005
Identification of a Gene that Increases Risk of MS Via a Pathway Involving UV Exposure (2005 - 2006)$109,375
- Funding
- National Health & Medical Research Council ($109,375)
- Scheme
- Grant-Project
- Administered By
- University of Tasmania
- Research Team
- Dwyer T; McKay JD; Dickinson JL; Ponsonby AL; Taylor BVM; Quinn SJ
- Period
- 2005 - 2006
- Grant Reference
- 333105
Tasmanian Prostate Cancer Study: Study of Molecular Events in large Tasmanian Prostate Cancer Families (2005)$14,200
- Funding
- Estate of Dr R.A. Parker ($14,200)
- Scheme
- Grant-Charitable Purposes in Tasmania
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; McKay JD
- Year
- 2005
Tasmanian Prostate Cancer Study (2005)$18,500
- Funding
- Mazda Foundation ($18,500)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL
- Year
- 2005
Tasmanian Prostate Cancer Study (TASPAC) (2005 - 2007)$60,000
- Funding
- Perpetual Trustees ($60,000)
- Scheme
- Grant-Trust Fund
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; McKay JD
- Period
- 2005 - 2007
The Tasmanian Parkinson's Disease Research Project: A Feasibility Study (2005)$14,742
- Funding
- Royal Hobart Hospital Research Foundation ($14,742)
- Scheme
- Grant-Research
- Administered By
- University of Tasmania
- Research Team
- Venn A; Dickinson JL; Srikanth V; D'Souza WJ
- Year
- 2005
Prostate Cancer: Sun Exposure And Candidate Genes Modifying Risk (2004 - 2006)$274,275
- Funding
- Commonwealth Department of Veterans Affairs ($274,275)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Dwyer T; Dickinson JL; Stankovich J; Blizzard CL; McKay JD
- Period
- 2004 - 2006
Identification of Genomic Regions Implicated in Hereditary Prostate Cancer in Tasmania by Genome-wide Scan (2004)$16,364
- Funding
- Royal Hobart Hospital Research Foundation ($16,364)
- Scheme
- Grant-Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; McKay JD; FitzGerald LM
- Year
- 2004
A Pilot Study to Examine Biological, Lifestyle and Genetic Risk Factors Associated with the Development of Multiple Non-melanoma Skin Cancers (2004)$22,000
- Funding
- University of Tasmania ($22,000)
- Scheme
- Grant-Institutional Research Scheme
- Administered By
- University of Tasmania
- Research Team
- Venn A; Dwyer T; Blizzard CL; Woods GM; Muller HK; Dickinson JL
- Year
- 2004
Molecular Genetics of Familial Prostate Cancer in Tasmania (2003)$20,000
- Funding
- Cancer Council of Tasmania ($20,000)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- McKay JD; Dickinson JL
- Year
- 2003
The MSR1 Gene and Risk of Prostate Cancer in the Tasmanian Population (2003)$11,667
- Funding
- Royal Hobart Hospital Research Foundation ($11,667)
- Scheme
- Grant-Research
- Administered By
- University of Tasmania
- Research Team
- McKay JD; Dickinson JL; Stankovich J
- Year
- 2003
A Pilot Study to Examine Biological, Lifestyle and Genetic Risk Factors Associated with the Development of Second and Subsequent Non-melanoma Skin Cancers in People with a History of Skin Cancer (2003)$18,000
- Funding
- Cancer Council of Tasmania ($18,000)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Venn A; Dwyer T; Blizzard CL; Woods GM; Muller HK; Dickinson JL
- Year
- 2003
Identification of Genes Causing Congenital Cataract (2002)$13,500
- Funding
- Royal Hobart Hospital Research Foundation ($13,500)
- Scheme
- Grant-Research
- Administered By
- University of Tasmania
- Research Team
- Dickinson JL; Easteal S
- Year
- 2002
Evaluation of the Norrie Disease, VEGF-B and VEGF-A Genes in Retinopathy of Prematurity (2001)$20,000
- Funding
- University of Tasmania ($20,000)
- Scheme
- Grant-Institutional Research Scheme
- Administered By
- University of Tasmania
- Research Team
- Sale MM; Dickinson JL
- Year
- 2001
The Glaucoma Inheritance Study in Tasmania (GIST): Investigating the Prevalence, Penetrance and Phenotype of Mutations in Genes Resulting in the Eye Disease, Glaucoma (2000)$11,177
- Funding
- Royal Hobart Hospital Research Foundation ($11,177)
- Scheme
- Grant-Research
- Administered By
- University of Tasmania
- Research Team
- Mackey DA; Dickinson JL
- Year
- 2000
Research Supervision
Current
5
Completed
19
Current
| Degree | Title | Commenced |
|---|---|---|
| PhD | Understanding the Triggers of Pollen Allergy in Tasmania: A novel molecular approach | 2018 |
| PhD | Investigating the Impact of Inherited and Somatic Genomic Variation on Prostate Cancer Risk and Development | 2019 |
| PhD | Identifying Genetic Variants Causal in Telomeropathy Associated Cancer | 2021 |
| PhD | Molecular drivers of metastasis | 2023 |
| PhD | Genetic variation in metastatic cancer | 2024 |
Completed
| Degree | Title | Completed |
|---|---|---|
| PhD | Understanding Prostate Cancer from a Tasmanian Perspective Candidate: Georgea Rigano Foley | 2023 |
| PhD | Epigenetic Regulation of Integrin ITGA2 and the Identification of Epigenetic Drivers of Bone Metastasis in Breast Cancer Candidate: Tristan Joseph Verhoeff | 2022 |
| PhD | Epigenetic Mechanisms in Prostate Cancer Metastasis to the Bone Candidate: Emma Jane Wilkinson | 2021 |
| PhD | The Aortopathy of Bicuspid Aortic Valve Candidate: Ashutosh Avadhoot Hardikar | 2021 |
| PhD | Identifying the Genetic Causes of Paediatric Cataract in Australian Families Candidate: Johanna Lee Jones | 2020 |
| PhD | Gene Regulation by RUNX1 in the Absence of Consensus Sequences Candidate: Alexandra Morgan Woodworth | 2020 |
| PhD | Using Families to Understand the Impact of Genetic Variation on Prostate Cancer Candidate: Kelsie Raspin | 2020 |
| PhD | Molecular Biomarkers for Seabird Age Estimation: Implications for ecological monitoring Candidate: Ricardo De Paoli-Iseppi | 2019 |
| PhD | Regulation of ITGA6 and ITGB4 Integrin Genes by RUNX1 and Epigenetic Mechanisms Candidate: Jessica Louise Mitchell | 2017 |
| PhD | Epigenomic and Genomic Analysis of Familial Prostate Cancer Candidate: Emma Cazaly | 2017 |
| Masters | On the Role of Risk-Associated Genetic Loci in Modulating Clinical Course in Multiple Sclerosis Candidate: Gongbu Pan | 2016 |
| PhD | The Anti-Cancer Activity of the Natural Product, Fucoidan, in Haematological Malignancies Candidate: Farzaneh Atashrazm | 2016 |
| PhD | Identifying Genetic Susceptibilities Underlying Familial Haematological Malignancies in a Tasmanian Family Resource Candidate: Nicholas Bayden Blackburn | 2015 |
| PhD | Regulation of the ITGA2 Gene in Prostate Cancer Candidate: Suyin Paulynn Chin | 2014 |
| PhD | Regulation of Inducible Immune Gene Expression in T Cells Compared to Macrophages Candidate: Lucy Damaris Apps | 2014 |
| PhD | Regulation of the LIFR and gp130 Genes by the RUNX1 Transcription Factor Candidate: Abeer Ahmed Qadi | 2012 |
| PhD | Investigating the Genetic Predisposition for Familial Haematological Malignancies Candidate: Elizabeth Mary Tegg | 2011 |
| PhD | The Genetics of Familial Prostate Cancer in Tasmania Candidate: Liesel Maria FitzGerald | 2007 |
| PhD | Investigating the Genetics of Primary Open-Angle Glaucoma in Tasmania Candidate: Jac Claire Charlesworth | 2006 |